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BY ALTERNATE GAMMA CHAIN CYTOKINES AND BY GEMCITABINE 
MEDIATED INHIBITION OF MYELOID DERIVED SUPPRESSOR CELLS  
 
By Hanh Kim Le, M.S. 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2008 
 
Major Director:  George Ford 
Professor, Physiology and Biophysics 
 
Successful treatment of cancer with adoptive immunotherapy (AIT) is dependent 
on the ability to produce large numbers of tumor-specific, functional T cells.  The purpose 
of this thesis is to explore ways in which T cell expansion could be augmented.  We have 
focused on exploring alternate gamma chain cytokines as stimulators of T cell proliferation 
and differentiation in addition to investigating the potential usefulness of gemcitabine 
(GEM) in abrogating the immunosuppressive effects of myeloid derived suppressor cells 
(MDSCs).  B16 melanoma sensitized draining lymph node cells that have been activated in 
vitro with bryostatin-1 and ionomycin (B/I) were expanded in either IL-7/15 or in IL-2.  
viii 
 
We found that IL-7/15 was superior to IL-2 in expanding T cells for AIT of pulmonary 
metastases.  Expansion of antitumor T cells was also improved by suppressing 
accumulation of MDSCs in mice bearing 4T1 mammary carcinoma using GEM.   GEM 
directly inhibits both 4T1 mammary carcinoma cells and MDSCs.  Its inhibition of 
MDSCs rescued tolerant T cells, augmenting both expansion and response to tumor 
antigen.     
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{CHAPTER 1: Introduction} 
 
 
 
Current Trends in Cancer: 
 
 In the United States, cancer is the second most common cause of death, accounting 
for 1 in every four.  According to the American Cancer Society, 2,437,180 new cases of 
cancer are expected to be diagnosed in the United States in 2008, not including 
noninvasive cancer of sites outside the urinary bladder 1. This is in addition to 
approximately 10.8 million Americans surveyed in 2004 living with a history of cancer. 
Over 1500 people are expected to die per day because of cancer this year, with an expected 
death toll of 564,6501. With so much of the population affected, either as a patient or living 
with someone with malignancy, developing better, more effective treatments is of the 
utmost importance. 
Cancer is a disease that afflicts all nations of the world, not just the United States. It 
accounts for 15.7% of total global deaths and has a greater mortality than HIV/AIDS, 
tuberculosis and malaria combined (Fig. 1). However, there has been a shift in the world 
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population that is affected by cancer.  Success in preventing and treating infectious 
diseases and in improving sanitation across the globe has helped increase life expectancy 
(from 50 in 1965 to 65 in 2005), allowing chronic diseases like cancer to become a 
growing concern internationally 2. Globalization has led to the spread of Western living 
standards, like smoking, unhealthy diets, lack of exercise and obesity.  This influence has 
fostered a rise in the incidence of cancer in poor and middle-income countries. Cancer is a 
relatively new concern in these countries, so while death rates for chronic illnesses have 
decreased in affluent countries due to early detection, preventative measures, public 
education, and better diagnosis and treatment options, there is an increase in death rates 
caused by chronic illnesses in developing nations. In 2005, one-quarter of the deaths 
observed in the industrialized nations were due to chronic illnesses compared to three-
quarters in developing countries2.  Much of the developing world is armed against acute 
infectious diseases but lack the support systems necessary to tackle the cost of public 
education and long term medical care.  In the United States, $8.1 billion is spent to 
diagnose and treat breast cancer each year with clinics and specialists available across the 
country.  In contrast, Pune, India has a single facility that provides comprehensive breast 
cancer services for about 3.5 million women3.  Half of all Indian women with breast cancer 
receive nothing in the way of treatment.  50% of cancers are caught early, in stage 0 or 1, 
in the U.S., but only 5% in South Africa.  In the face of these challenges, it becomes all the 
more imperative that effective treatments for cancer are developed.  Not just effective, but 
inexpensive and practical.  AIT as it is right now, is neither of these.  Therefore, much 
work is still needed to make this treatment option optimal for combating cancer.  In 
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addition to building up the cancer support infrastructure, increasing awareness, bettering 
prophylactic measures, improving diagnoses, and funding more cancer-related research, 
developing manageable and accessible treatment options will help ensure equal access to 
care for cancer patients world-wide. 
              
Figure 1. Causes of Death Worldwide in 2005 2 
 
 
 
Cellular Immunotherapy as a Therapeutic Approach: 
 
The foundations of cellular therapy was established in 1957, when Barnes and 
Loutit provided the first evidence of the ability of the immune system to target and 
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eradicate cancer4.  Using a murine model of leukemia, they hypothesized that irradiation 
alone is not enough to cure leukemia due to radiation resistant leukemic cells that can 
cause relapse in treated mice.  However, irradiation followed by homologous bone marrow 
transplantation may eliminate surviving leukemic cells by stimulating an immune response 
against the host.  Mice with leukemia that have been irradiated and grafted with 
homologous bone marrow were completely cured while mice grafted with isologous bone 
marrow were not. The graft versus host effect induced by the homologous marrow was 
able to eliminate residual leukemic cells that survived irradiation. These mice showed no 
signs of leukemia upon histological examination and suspensions made from their spleens 
did not cause leukemia in normal mice when injected intraperitoneally, which stands in 
contrast to mice grafted with isologous marrow. The results of these experiments showed 
that cellular immunity can be manipulated against cancer and launched a new direction for 
research in the treatment of cancer.  
Following this, Southam et al. demonstrated that the growth of cancer is amenable 
to control by immune mechanisms present in the host through autologous and homologous 
transplant experiments admixed with leukocytes5. When autologous leukocytes were 
present, there was inhibition of tumor growth in 21 of 42 patients implanted 
subcutaneously with their own tumor cells. In groups implanted with autologous cancer 
cells in addition to homologous leukocytes or autologous plasma, there was a 33% 
inhibition of cancer growth (3 of 9 patients and 7 of 21 patients, respectively). In patients 
receiving homografts, 7 of 9 patients showed tumor inhibition when leukocytes from the 
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cancer donor were admixed and 2 of 8 patients showed inhibition when control leukocytes 
from healthy donors were used. Although the sample size of the study is too small to give 
statistically significant results, this study suggests the presence of specific inhibitory 
leukocytes in cancer patients that perhaps exert some degree of control on the growth of 
cancer cells of that individual.  
The studies by Barnes and Loutit and Southam et al. suggest that a defense 
mechanism against cancer growth exists in patients and involves cellular immunity. This is 
an important concept because cancer cells are not foreign to the host body.  Thus, without 
support of hard science, it would be inconceivable that the host immune system would 
recognize and annihilate good cells that have gone bad.  Since then, there has been much 
evidence of endogenous immune responses against cancer that warrant developing 
immunotherapy as a treatment for cancer.  For example, Her-2/neu is an oncogenic protein 
that is overexpressed in about 20% of human adenocarcinomas and is also overexpressed 
in cancers of the breast, ovary, uterus, stomach, and lung6.  Using quanititative ELISA for 
the detection of human HER-2/neu specific antibody response or Western Blotting, 
humoral immunity (IgG and IgA) has been detected in patients bearing cancers 
overexpressing Her-2/neu, like colorectal, ovarian, and breast cancer7-9.  Tumor specifc 
CD-4 T cells have also been detected in the peripheral blood of patients bearing breast or 
ovarian cancer and these cells proliferated in response to HER-2/neu protein and peptides, 
demonstrating the existence of cell mediated immunity against Her-2/neu cancers8, 9.  
Measuring interferon-gamma (IFN-γ) release and tumor cytolysis, endogenous antitumor 
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CD-8 T cells have been observed in melanoma patients10, 11.  Immunocytochemical 
analyses of human tumors show the presence of tumor infiltrating lymphocytes (TILs), 
including machrophages, neutrophils, natural killer cells, eosinophils, T cells, and B 
cells12.  The accumulation of antigen specific T and B cells at the tumor site supports the 
notion that cancer cells are immunogenic. The presence of tumor reactive T cells and the 
circulation of tumor targeting antibodies show that priming of the immune system against 
malignant cells is functional during neoplastic transformation. Further evidence that the 
immune system is capable of fighting cancer in situ comes from experiments that show the 
ability of TILs isolated from tumor sites to expand in vitro and cause tumor regression in 
autologous patients upon adoptive transfer13.  The observation that patients develop 
spontaneous responses to antigens being expressed by autologous tumor suggests that it 
may be possible to boost and optimize this immunity to therapeutic levels through 
immunotherapy.  If the host immune system is inhibited by cancer then its restoration 
should increase responsiveness to tumor tissue and aid in the inhibition of malignancy.   
Although spontaneous immune mechanisms exist against cancer, they are unable to 
control the growth of even antigenic tumors.  Tumors evade host immune system through 
masquerading strategies and through suppression of immune cells. Many mechanisms have 
been proposed to account for this immune dysfunction, including the secretion of 
inhibitory factors (e.g., transforming growth factor (TGF-ß), interleukin-10 (IL-10), 
phosphatidyl serine, gangliosides, nitric oxide, prostaglandin E2, and reactive oxygen 
intermediates), downregulation of major histocompatability complexes and costimulatory 
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signals on tumor cell surface, loss of tumor antigen expression, and induction of regulatory 
immune cells12, 14, 15.  These changes prevent tumor recognition and inhibit immune 
effector functions.  TILs harvested at tumor sites are often deficient in proliferative 
response and cytotoxic function in vitro, but are able to recover these biologic processes 
after purification from tumor cells.  A hypothesis proposed by Radoja and Frey suggests 
that T cells receive an abortive apoptotic signal from tumor cells that inactivates T cell 
receptor (TCR)-mediated signal transduction and causes T cell anergy12.  This mechanism 
involves the incomplete activation of the apoptotic pathway, which leads to proteolysis of 
TCR-ζ and inhibits transduction of TCR signaling when the T cell recognizes a tumor 
antigen.  Inactivation of TCR- ζ prevents the activation of the MAP kinase pathway, which 
results in down-regulated cytokine transcription, failure to transit the cell cycle, loss of 
proliferation, and loss of effector function.  Thus, TILs remain in G0/G1 and are 
functionally anergic.  Upon removal of the pro-apoptotic signal, TILs can again express 
TCR-ζ and reenter the cell cycle.  This hypothesis is based on the observation that TILs 
express both Fas and FasL and are unable to respond to stimulation via the TCR 16.  
Lymphocytes recovered from patients with advanced head and neck cancer have 
abnormalities in signaling via the TCR.  Compared with normal lymphocytes, those 
isolated from cancer patients have defects in expression and function of signaling 
molecules involved in the TCR pathway, including decreased expression of the ζ and ε 
chains, decreased Ca2+ flux, and impared kinase activity.  Defects in TCR are 
posttranscriptional and inhibitors of apoptosis prevent ζ chain loss induced by TIL 
interaction with tumor cells 16.  These observations suggest that signaling defects found in 
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lymphocytes from cancer patients might be caused by apoptosis induced by the tumor.  
Through this immunosuppressive mechanism and others, the tumor microenvironment 
effectively puts the host cells in a state of tumor tolerance. 
 
Failure of immune surveillance is caused by both immunosuppression as well as 
immune ignorance.  Peripheral tumors may successfully grow because they remain outside 
the immune system and are ignored long enough to become well established and no longer 
amenable to rejection by the endogenous immune responses. Ochsenbein et al. 
demonstrated a correlation between lack of CTL priming and absence of tumor antigens in 
the lymph nodes and spleens of mice with growing fibrosarcoma tumors that were initially 
implanted as solid tumor pieces17.  Tumor escape in these mice was not by T cell anergy or 
deletion as revealed by following CFSE labeled T cells after adoptive transfer and was not 
caused by immune escape or MHC I modulation.  Isolated tumor cells were all susceptible 
to effector CTL specific for the tumor antigen, glycoprotein of lymphocytic 
choriomeningitis (LCMV).  Thus, it was hypothesized that tumor cell processing in 
secondary lymphoid organs may be crucial in the induction of an immune response against 
peripheral tumors.  Antigens that do not enter lymph tissues at sufficient levels do not 
induce an efficient CTL response, thus, allowing peripheral tumors that are highly 
antigenic to be ignored by the immune system.  Subcutaneous inoculation of ALY x ALY 
mice lacking all secondary lymphoid organs with 107 MC-GP fibrosarcoma cells in 
suspension always caused tumors but never in C57BL/6 control mice.  Control mice were 
positive for both LCMV-GP-Specific PCR of DNA extracted from the lymph nodes and 
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primed CTL activity.  No CTL response was induced in ALY x ALY mice.  However, 
inoculation directly into the spleen induced a CTL response.  This verifies the importance 
of antigen presentation.  Growing tumors in C57BL/6 mice implanted with MC-GP solid 
tumor pieces were susceptible to rejection if a strong and long-lasting antigen-driven CTL 
response was induced and maintained in vivo.  Thus, restoration of immune surveillance by 
immunization against the established tumors was key in the success of treatment.  
  
Despite barriers to immune function against cancer, a very important observation is 
made: TIL dysfunction is reversible.  Although CD8+ TILS cannot lyse tumors expressing 
immunogenic antigens in situ, they are able to in vitro.  This implies that the T cells have 
intact effector function, which is inhibited at the site of tumor growth.  Removal of the T 
cells from the tumor environment and culture with IL-2 reversed the dysfunction 14.  In 
addition, excision of the tumors from patients or animals restored ζ chain expression and 
the TCR signal transduction pathway.   
 
             The discovery of endogenous immune responses against cancer has validated 
immunotherapy of cancer by confirming three important points: 1) cancer cells express 
immunogenic proteins, 2) the body has cells that can recognize and mount a response 
against these proteins, and 3) this response is often immunosuppressed by the cancer 
microenvironment.  Subsequent unveiling of tumor associated antigens further boosts 
immunotherapeutic efforts.  Many tumor associated antigens have been identified, 
allowing for a very controlled and highly selective targeting of cancer cells. Because of the 
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predominant role of cell-mediated immunity in cancer eradication, efforts to identify tumor 
antigens have focused on those recognized by T cells.  Antigens specifically involved in 
cancer rejection have been identified by isolating tumor infiltrating lymphocytes from 
patients with metastatic melanoma that can induce tumor rejection when adoptively 
transferred to the autologous cancer patient18, 19.  Recognition of tumors by TILs can be 
assayed by in vitro tumor cell lysis or by cytokine release.  TILs associated with tumor 
regression were used to screen cDNA libraries derived from tumors.  Genes that encode 
TIL-reactive antigens were identified by transfecting cDNA libraries from melanoma into 
breast cancer cells.  Stable transfectants were isolated and tested for the ability to induce 
cytokine release from TILs.  An alternative method that was used employed a transient 
expression system that screens pools of cDNA for TIL-reactivity.  The genes were then 
cloned and tested for immunogenicity.  Six genes recognized by TILs were thus found, 
including MART-1, gp100, tyrosinase, tyrosinase-related protein 1, p15, and ß-catenin18, 
19.  Of these, all but ß-catenin are non-mutated forms of genes found in normal cells.  
MART-1, gp100, and tyrosinase are differentiation antigens present on melanomas and 
normal melanocytes.  Tyrosinase-related protein 1 is a normal melanoma differentiation 
antigen that is the product of translation from an open reading frame different from the 
normal protein.  Likewise, the p15 antigen is derived from a normal gene but expression of 
this antigen is limited to melanoma and absent at the cell surface of normal cells.  The 
discovery of these antigens exemplify a biological process that further supports the use of 
immunotherapy against tumors.  That is, tumors cells, due to genetic instability, often 
express proteins that are usually limited in expression on normal cells and therefore, below 
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threshold level for T cell recognition.  Immunotherapy can be used to utilize this difference 
in expression to break T cell tolerance and target malignant cells with little or no harm to 
healthy cells.  The ß-catenin antigen represents another class of antigens that can be 
exploited: unique tumor associated antigens that arise from mutations of normal genes.   
New cancer antigens have also been identified by the serologic analysis of 
recombinant cDNA expression libraries (SEREX) and by eluting peptide antigens from 
antigen presenting cells (APCs) and screening autologous tumor-specific T cells for 
reactivity20.  At least 90 human tumor antigens recognized by T cells have so far been 
identified, lending promise to clinical application 18-23.   Identification of these 
immunogenic epitopes allows host T lymphocytes to be sensitized in vitro by host APCs, 
expanded to therapeutic numbers, and eventually reintroduced into cancer patients to lyse 
antigen bearing tumor cells and secrete cytokines that inhibit tumor progression21, 23, 24.   
Clinically, TILs sensitized to gp100 epitopes have been shown to cause >50% tumor 
regression when adoptively transferred to autologous melanoma patients along with IL-2 
and similar tumor specific immune responses have been observed in vivo with transfer of T 
cells generated by in vitro stimulation with autologous APCs pulsed with specific tumor 
associated antigens22, 25, 26.  Infusion of TILs recognizing tyrosinase with IL-2 into a patient 
with multiple established lung, mucosal, and subcutaneous metastases caused a complete 
remission and retreatment upon relapse led to complete regression 19.   
 
Because tumor antigens tend to be poorly immunogenic, modifications can be 
made to immunodominant peptides to increase binding to major histocompatability 
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complexes6.  Immunotherapy can be performed with immunodominant peptides alone, 
combined with adjuvants, pulsed onto APCs, or in combination with cytokines and 
costimulatory molecules to enhance the immune response6, 18, 22, 24-27.  With known 
antigens, T cell receptors can be engineered to bind with high affinity to tumor cells, 
allowing for more potent and more selective immune responses. Hanson et al. created a 
murine TCR transgenic model for the methylcholanthrene-induced fibrosarcoma CMS5 
called DUC1828.  Transfer of DUC18 splenocytes containing transgenic T cells with TCRs 
that are H-2Kd restricted and specific for syngeneic CMS5 fibrosarcoma rejection antigen, 
mutated ERK2, to normal BALB/c mice conferred a resistance to CMS5 challenge. Using 
DUC18 splenocytes, adoptive immunotherapy of established CMS5 tumors caused 
rejection of the tumor without the aid of other forms of therapy.  Rejection of tumors by 
AIT is preceded by lymphocyte infiltration of the tumor site as revealed by histological 
examination.  By defining specific targets, the identification of tumor associated antigens 
has been demonstrated to augment immunotherapeutic efforts against cancer.  
Evidence of spontaneous immune responses against tumors, of immunosuppression 
induced by the cancer milieu, of immunological ignorance, and of tumor associated 
antigens all suggest that the host immune system can be manipulated and optimized to 
target cancer. Traditional therapies, such as irradiation, chemotherapy, and surgery, do not 
prevent metastatic spread of disseminated tumor cells.  Immunotherapy attempts to prevent 
metastatic spread, eliminate the tumor, and prevent recurrence through the development of 
memory lymphocytes. 
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{CHAPTER 2: Principles of Adoptive Immunotherapy} 
 
Immunotherapy uses the body’s natural defenses against pathogens to target 
harmful cancer cells. Adoptive immunotherapy (AIT) relies on manipulation of a host’s 
lymphocytes to produce tumor-specific cells that are optimized in effector functions.  T 
cells are harvested from a patient and cancer specific T cells are expanded in vitro then 
reintroduced into the host.   These optimized T cells will hopefully mount a response 
against the malignant cells and eradicate the tumor mass. AIT circumvents the in vivo 
constraints that influence the magnitude and avidity of T cell responses against tumor, 
allowing the generation and activation of lymphocytes away from the suppressive tumor 
environment.  In addition, it allows for the treatment of the host before reintroduction of 
the selected cells; thereby, providing the optimal environment for antitumor responses. 
Successful adoptive immunotherapy depends on several factors.  The type of cells chosen 
for transfer mediates the potency of the immune response induced against the tumor.  The 
effectiveness of the treatment is contingent upon the ability to generate and expand, in 
vitro, tumor specific and reactive lymphocytes from tumor bearing hosts.    The in vitro 
avidity of these lymphocytes must extend in vivo to the cancer site.  Thus, creating a 
lymphodepleted host environment and reversal of immunosuppression in the host become 
essential in achieving therapeutic results. 
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Using T cells for Adoptive Transfer:  
Cytotoxic CD8+ T cells have many advantages over other cells as the focus for 
adoptive immunotherapy.  They can specifically target tumor cells through recognition of 
differentially expressed tumor proteins, have long clonal lifespans, are amenable to genetic 
manipulation, have multiple, potent tumor-killing mechanisms, and can provide long-term 
protection by developing memory responses.  CD8+ T cells that have become activated 
can kill tumor directly through cytolysis or secrete cytotoxic cytokines (e.g., tumor 
necrosis factor), cytokines that recruit or activate other immune cells that are tumoricidal 
(e.g., granulocyte-monocyte colony stimulating factor and interferon-γ), and cytokines that 
affect tumor vasculature (e.g., IL-12). 
Common sources of CD8+ T cells are the tumor tissue (tumor infiltrating lymphocytes – 
TILs), spleen, blood, and draining lymph nodes (DLNs).  TILs represent a heterogeneous 
population of lymphocytes that are found within the tumor tissue.  Their migration to the 
tumor site is thought to have been the result of a tumor antigen (Ag)-specific immune 
response.  Hence, TILs are already exposed to tumor cells and recognize them as 
immunogenic. Schiltz et al. characterized TILs from melanoma, colorectal cancer, renal 
cell carcinoma, breast, and sarcoma and found that they are dominated by T cells, either 
CD4+ or CD8+, depending on culture conditions29.  TILs expanded for low-dose therapy 
(TIL reinfusion numbers of 5x108-109) were predominantly CD4+ in 76% of 42 cultures 
while high-dose TILs (infusion numbers of > 5x109-1010) were predominantly CD8+ in 
84% of 44 cultures.   
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TILs are isolated from the tumor mechanically or through enzymatic digestion and 
made into a single cell suspension.  The suspension is then incubated in IL-2, which 
enriches for T lymphocytes and allows ex vivo expansion to sufficient numbers 29, 30.  
Successful therapy using TILs has been noted in several in vivo studies30, 31.  Adoptive 
transfer of TILs with systemic administration of IL-2 in a lymphodepleted host has resulted 
in the elimination of established micrometastases in several tumor models, including 
MCA-105 sarcoma, MC-38 colon adenocarcinoma, the B16 melanoma, MCA-106 
sarcoma, and 1660 bladder carcinoma 30.  The use of TILs has translated into human 
therapy causing significant regression of tumor masses in the clinic13, 19, 22.  However, 
despite promising results, harvesting TILs with specific reactivity in vivo has met with 
limited success and the overall process is time and labor intensive.  The mean number of 
days to reach successful initiation of culture is 35±24 days and expansion from culture to 
treatment ranged from an average of 59 days for low-dose TIL therapy to an average of 80 
days for high-dose therapy.   
   
   While TILS provide an attractive source of Ag sensitized T cells, this source is 
quite limited.  Not all cancer patients have solid tumors that are accessible, making TILs 
available only to a minority of patients.  TILs are a heterogeneous population of 
lymphocytes and may only contain a few cells that have antitumor activity. Thus, much 
effort has been made to generate tumor specific T cells derived from other sources.  Our 
lab uses the draining lymph nodes as the source of T cells after vaccination with whole 
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tumor cells.  The use of DLNs is based on observations that tumor antigen presentation 
after vaccination of the host occurs in the lymph nodes that drain the tumor site32.  The 
works by Maass and colleagues revealed that after subcutaneous inoculation of mice with 
IL-2-secreting M-3 melanoma cells, there was no indication of T cell priming at the site of 
injection.  Rather, mRNA recovered at the vaccination site showed an accumulation of 
natural killer cells, macrophages, and granulocytes.  Here, macrophages ingest tumor cells 
and are hypothesized to migrate to DLNs, where they act as antigen presenting cells to 
prime T cells.  This hypothesis is supported by several observations: latex beads are 
transferred from tumor cells to macrophages at the vaccination site, draining lymph nodes 
become enlarged in vaccinated animals, and mRNA markers for activated T cells (IL-2, 
IL-4, CTLA-4, and CD69) with cytotoxic activity (granzyme B and IFN-γ) are found in the 
DLN only after vaccination.  Identifying and isolating DLNs in the clinic has become 
practical with the development of sentinel node mapping using isosulfan blue (IB) dye and 
radioactive tracers33.  IB injection has allowed for the consistent identification of 
immunologically active DLNs within a regional lymphatic basin that stems from the 
primary tumor.  Injection of the dye into the footpad 10 days after vaccination with tumor 
cells using the same inoculation site led to blue stained popliteal lymph nodes and injection 
into the flank stained axillary and inguinal lymph nodes.  T cells harvested from DLNs 
stained with IB show anti-tumor activity upon adoptive transfer, causing complete 
regression of 4T07 mammary carcinoma in all treated mice.  Sentinel node mapping is 
important in translating work in mice to human clinical trials, allowing for the reduction of 
morbidity associated with extensive and unnecessary removal of irrelevant lymph nodes. 
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Unlike TILs that have been exposed to tumor cells and may contain tumor reactive 
lymphocytes, CD8+ T cells from sites outside the tumor must be sensitized.  Subjects can 
be primarily sensitized to the tumor in vivo by antigen immunization and secondarily 
sensitized in vitro with the same antigen to select for T cells with better tumor reactivity.  
Numerous tumor antigens have been identified and can be exploited towards this end.  
Many protocols also employ whole tumor cells or tumor cell lysates as the source of tumor 
antigens for vaccination.   
Generation and Activation of Tumor Reactive T cells: 
Effective adoptive therapy depends on lymphocytes that can mount a specific 
immune response against tumor cells while leaving normal cells unharmed.  Tumor antigen 
specific T cells can be generated using a variety of methods.  Classical protocols have used 
whole tumor cells as the source of tumor antigens to sensitize and stimulate T cells.  
Advances in technology have allowed for the identification of specific tumor antigens that 
are conducive to a more selective immune response.  Pharmacologic agents have also been 
developed that activate T cells without the need for tumor cells or antigens.    
There are many advantages to using whole tumor cells to sensitize and stimulate T 
cells.   Whole cells expose T cells to diverse antigens that are present on the tumor without 
knowing the exact peptides responsible for tumor rejection.  A polyclonal repertoire of T 
cells can be generated that mitigate the impact of tumor escape mechanisms, like mutation 
of specific antigen(Ag) or downregulation of antigen expression.  In addition, Dalyot-
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Herman et al. found that whole tumor cells expressing an antigen recognized by T cells are 
more immunogenic than soluble Ag peptide34.  This is perhaps due to better Ag 
presentation or stronger costimulation provided by the tumor cells.  To generate tumor 
specific T cells in our lab, we inoculate naive mice with whole tumor cells and harvest 
draining lymph nodes.  This protocol has induced tumor reactive T cells to several tumor 
models, including fibrosarcomas, 4T07-IL-2 and 4T1 mammary tumor cells, P815 
mastocytoma cells, and B16 melanoma cells33, 35, 36.      
Shu et al. performed in vitro sensitization with viable tumor cells and IL-2 using 
the weakly immunogenic murine tumor, MCA105  37.  Their work showed that 
nontherapeutic cytotoxic T cells can acquire antitumor reactivity capable of mediating 
regression of established pulmonary metastases.  Therapeutic lymphocytes harvested from 
the draining lymph nodes can be generated by in vitro sensitization with whole tumor cells 
for a broad range of host tumor burdens as well as durations of tumor growth.   
The usefulness of tumor cells is limited by availability.  Not all patients have cells 
that can readily be isolated.  Another disadvantage of using tumor cells is that they are 
generally not immunogenic.  However, scientific advances have arisen to circumvent this 
problem.  For example, tumor cells can be transfected with genes for adjuvants that are 
highly immunogenic.  For example, one of the tumor models used to generate tumor-
specific lymphocytes in our lab is B16–GMCSF.  GM-CSF is a cytokine that acts as an 
adjuvant by stimulating dendritic cells, macrophages, and other granulocytes, activating 
and attracting these effector cells to the tumor.  Another method to enhance T cell 
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responsiveness to tumor cells is to genetically engineer tumor cells to secrete factors like 
IL-2 that enhance the cellular immune response.   
In addition to tumor cells, T cells can be sensitized and activated by proper Ag 
presentation using autologous antigen presenting cells (APCs) pulsed with a specific tumor 
peptide.  However, this requires precise knowledge of the relevant tumor antigen epitope.  
Synthetic peptides are readily available; and thus, bypass the quantitative limitation that 
thwarts the use of whole tumor cells.  APCs pulsed with synthetic peptides have been used 
to induce the formation of effector T cells that prevent the growth of solid tumor in 
C57BL/6 mice when adoptively transferred 5 days after subcutaneous injection of EG7 
OVA transfected thymoma cells34.  Similarly, Valmori et al. exploited a known 
melanocyte associated antigen, Melan-A, to synthesize an analogue that demonstrates 
improved in vitro T cell expansion and cytotoxicity when pulsed onto peripheral blood 
mononuclear cells derived from melanoma patients38.  Yee et al. has transitioned this 
protocol to clinical trials with successful regression of metastases using MART-1 and 
gp100-specific CD8+ T cells generated from the peripheral blood of patients with 
metastatic melanoma39.  These T cells were sensitized to melanoma by incubation with 
autologous dendritic cells pulsed with the specific peptide epitopes.   
As demonstrated by Valmori et al., better recognition of known tumor epitopes has 
been achieved by genetically modifying the antigen to create analogues with high affinity 
binding.  T cell receptors can also be enhanced to foster antigen recognition.  In their 
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experiments, Dalyot-Herman et al. used an OT-1 TCR transgenic T cell model that is 
specific for OVA peptide bound to H-2Kb and demonstrated both the strengths and 
weaknesses of using T cells with transgenic TCR recognizing a single peptide 34.  The use 
of a transgenic TCR that recognizes an immunogenic tumor peptide ensures that once 
activated, all the T cells are Ag responsive; thereby, ensuring quality with limited quantity.  
Dalyot-Herman et al. were able to delay the establishment of solid tumor for 45 days in 
40% of mice with adoptive transfer of antigen specific effector CD8+ T cells and this 
tumor free condition lasted up to 60 days.  However, the tumor eventually grew, escaping 
the immune response by loss of the antigen that was recognized by OT-1 T cells.  Tumor 
cells harvested from these mice no longer triggered cytolytic activity by OVA specific 
CD8+ T cells.  Tumor antigen loss variants generated by mutation of the recognized 
antigen or loss of expression have also been observed in human therapy 39.  Observations 
such as these argue against becoming reliant on a single antigen for therapy, despite the 
ability to specifically target cancer cells over healthy cells.   
  Whether using whole tumor cells or specific antigens to activate T cells, the 
optimal protocol for generating T cells with strong antitumor specificity and reactivity 
combines in vivo immunization or priming with ex vivo sensitization. Although tumor 
bearing hosts already have a milieu of tumor antigens, these antigens may be concealed 
from the immune system, whether by physical barriers or tumor induced defects in antigen 
presentation.  Vaccination of the host exposes the immune system to tumor antigens that 
may otherwise be inaccessible in vivo.  Without in vivo priming to the tumor, in vitro 
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sensitization is not therapeutic.  Luking and colleagues demonstrated this concept using the 
A20 BALB/c derived B cell lymphoma and found that among the in vitro stimulated T cell 
lines, only those from vaccinated mice provided protective immunity40.  T cells from naive 
mice showed A20 reactivity in vitro but were not protective in vivo.  They establish that T 
cells derived from vaccinated mice accumulate rapidly during in vitro stimulation 
compared to those from naive mice and have better in vivo survival after withdrawal of the 
antigenic stimulus.  The need for in vivo priming is also substantiated by the works of Shu 
et al., which verify that activation by in vitro sensitization is a secondary response 
dependent on primary in vivo activation37. Luking et al. argued that along with in vivo 
priming, in vitro sensitization of T cells is also necessary for optimal adoptive therapy.  
When T cells were enriched in vitro without restimulation, a nonprotective population with 
a broad TCR Vβ repertoire resulted.  This indicates that clonal expansion was not induced 
because the TCR repertoire expressed by the T cell population would have been restricted 
as a consequence.  Because of the heterogeneity of lymphocytes obtained from a host, in 
vitro resensitization allows for the enrichment of lymphocytes with tumor-reactivity.  It 
also prevents death by neglect, a process by which T cells that are not properly stimulated 
through the TCR undergo senescence and apoptosis.  Proper in vitro sensitization improves 
T cell fitness and allows optimal response to homeostatic cytokines.       
Ex vivo activation of T cells can be achieved without the need for tumor antigens.  
T cells can be stimulated pharmacologically through the use of small molecules that 
activate pathways involved in T cell activation via the TCR.  Clonal expansion of naive T 
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cells requires a primary signal from the recognition of a peptide presented by a major 
histocompatibility complex (MHC) as well as a secondary co-stimulatory signal provided 
by the antigen presenting cell.  The recognition of the MHC:peptide complex is performed 
by the T cell receptor, which is a heterodimer composed of two transmembrane 
glycoprotein chains called αand β that each contain a variable domain and a constant 
domain.  The complete TCR is a complex of this antigen recognition component and 
invariant signaling proteins, CD3γ, CD3δ, CD3ε, and the ζ chain.  These invariant 
accessory chains have immunoreceptor tyrosine-based activation motifs (ITAMs) 
sequences.  The ITAMs contain tyrosine residues that are phosphorylated by receptor-
associated Src-family tyrosine kinases, Lck and Fyn.  In addition, antigen receptor 
signaling is enhanced by co-receptors, CD8 in cytotoxic T cells.  Upon recognition of an 
MHC:peptide complex by the TCR and CD8 binding to the α3 domain of MHC class I, 
clustering of the receptors is induced to bring together players necessary for signal 
transduction.  This allows the CD45 tyrosine phosphatase to remove inhibitory phosphates 
at the carboxy terminus of the Src-family kinases and thereby, allow the activation of Lck 
and Fyn.  Lck is constitutively associated with the CD8 co-receptor and phosphorylates the 
CD3ε chains.  Fyn phosphorylates the ζ chains which recruits the ζ –chain associated 
protein (ZAP-70).  ZAP-70 is phosphorylated and activated by Lck and subsequently 
phosphorylates the adaptor proteins LAT and SLP-76, which binds and activates Tec 
kinases that phosphorylate phospholipase C-γ (PLC-γ) and guanine exchange factors 
(GEFs) that activate Ras G protein.  PLC-γ cleaves phosphatidylinositol biphosphate 
(PIP2) into diacylglycerol (DAG) and inositol triphosphate (IP3).  IP3 increases intracellular 
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Ca2+ levels activating calcineurin, a phosphatase that activates the nuclear factor of 
activated T cells (NFAT).  DAG and Ca2+ activate protein kinase C (PKC), which activates 
NFκB.  Ras activates the MAP kinase cascade which activates Fos, a part of the AP-1 
complex.  NFAT, NFκB, and AP-1 are transcription factors that induce specific gene 
expression, resulting in IL-2 production, upregulation of high affinity IL-2 receptor, T cell 
proliferation, and T cell differentiation.   
The need for antigen and co-receptor stimulation are circumvented by the use of 
bryostatin-1 and ionomycin, a protocol that was first established in our lab.  Bryostatin-1 is 
a macrocyclic lactone that activates PKC during short exposure, but induces PKC 
inhibition by causing depletion of the kinase during prolonged exposure41.  It has also been 
shown to have in vitro and in vivo antitumor activities, inhibiting growth, activating 
apoptosis, inducing differentiation, and enhancing the effects of chemotherapy.  
Bryostatin-1 as a single antitumor agent has gone through phase I and phase II clinical 
trials against various cancers with little efficacy41.  However, the ability of short duration 
stimulation with B/I to activate PKC serves as a promising drug to activate T cells used for 
AIT.   
Bryostatin-1 in conjunction with ionomycin, a calcium ionophore stimulate the 
TCR by activating PKC and increasing intracellular calcium concentrations.  Stimulation 
with bryostatin-1 and ionomycin (B/I) alone do not expand lymphocytes in culture but 
together induced 269-28,206-fold expansion of human breast cancer DLN T cells cultured 
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in IL-2 35, 42.  Breast DLN cells after a single dose of B/I at 50nM pulsed for 18hr caused 
expansion in IL-2 for up to 10 days, after which cell number declined.  However, a 
restimulation with B/I +IL-2 extended proliferation for at least another week42.   
Because the DLN are composed of a mixed population of lymphocytes, we 
questioned whether B/I is specific in its mode of action.  Precursor frequency analysis of 
antigen sensitized cytotoxic T cells from tumor vaccinated mice show 100-fold increase in 
the incidence of sensitized CD8+ T cells after pulsing with B/I 42-44.  Unsenstitized T cells 
show no significant cytolytic activity after expansion with B/I + IL-2.  Thus, it was 
concluded that B/I+ IL-2 treatment of DLN lymphocytes selectively activates T cells 
already sensitized to the tumor.  Indirect evidence was provided for this selective 
expansion of pre-effector lymphocytes sensitized to tumor cells.  No cytotoxic T cell 
activity was observed in vitro against autologous tumor despite recognition of the tumor 
resulting in IFN-γ secretion and in vivo tumor regression upon AIT 36, 42.  Direct evidence 
comes from experiments performed on CD62Llow cells enriched from DLNs of tumor 
bearing mice.  CD62L is a lymph node homing receptor that is down-regulated in antigen 
sensitized T cells, allowing the lymphocytes to traffic to tumor sites.  Thus, L-selectin is a 
marker for effector (CD62Llow) versus naive (CD62Lhigh) T cells.  B/I stimulation and 11 
days of culture in IL-2 caused a 12-fold greater expansion of CD62Llow cells than 
CD62Lhigh populations and 33-fold more IFN-γ secretion in response to autologous tumor 
cells44.  AIT of 4 day old and 10 day old 4T07 flank tumors showed complete regression 
when cells transferred were CD62Llow or unsorted compared to no tumor regression when 
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CD62Lhigh lymphocytes were used.  In addition, it was demonstrated that cured animals 
were protected from tumor rechallenge a month later.  Thus, B/I preferentially expands 
primed lymphocytes that can eliminate tumor as well as provide memory and resistance 
against tumor relapse.  This activation is probably specific to sensitized T cells because of 
the need for costimulation to activate naive, but not primed T cells.  The potency of B/I 
expanded DLN cells against tumors was demonstrated even when transferred without 
exogenous IL-236.  B/I expanded DLN cells are able to cause complete regression of lung, 
metastases, liver metastases, and intradermal tumors and protects cured hosts from tumor 
challenge35, 36.  The antitumor effect is specific and demonstrates the ability of DLN cells 
to traffic to the tumor site.            
 A well supported model of T cell activation suggests that proliferation, 
differentiation and death are progressive processes.  This progression is regulated by signal 
strength which is determined by a multitude of factors: antigen concentration and antigen 
affinity determines the rate of TCR triggering, the presence of costimulation regulates the 
extent of signal amplification, and the duration of the interactions between T cells and 
APCs determines the duration of signaling.  Gett et al. has shown that T cells that receive 
strong stimulation (anti-CD3 antibody + IL-2 + anti-CD28 antibody) survive in the 
absence of cytokines and accumulate in the presence of IL-7 and IL-15 while those that 
received weak stimulation (anti-CD3 + IL-2) did not accumulate in response to the 
cytokines and died by neglect45.  The effect of signal strength also carries on in vivo.  T 
cells receiving a strong signal proliferate extensively compared to those receiving a weak 
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signal.   We have demonstrated that B/I is able to provide strong TCR stimulation that 
allows T cell survival and function in vivo without the need for concomitant application of 
IL-2, which is needed with other protocols22, 25, 26.  This not only reduces the toxicities 
associated with infusion of exogenous cytokines, but also cuts back cost of the treatment.  
Thus, it is our preferred method for T cell activation.  
  
In vitro Expansion of Tumor Reactive Lymphocytes 
Expansion of T cells in vitro is dependent on cytokines of the interleukin family, 
especially the subset that signals via the common γ chain.  Interleukins are soluble 
signaling peptides produced by leukocytes that regulate the activity of cells of the immune 
system in an autocrine or paracrine manner.  They function in controlling the growth, 
development, and differentiation of lymphocytes and act as effector molecules of activated 
T cells.  Interleukin-2 (IL-2) has been the standard cytokine for T cell expansion both in 
animal models and in clinical settings13, 14, 22, 24, 29, 35, 36, 43. Its receptor consists of three 
subunits: α, β, and γ.  The β and γ chains are found on resting T cells and together form a 
receptor for IL-2 with intermediate affinity, allowing resting T cells to respond to high 
levels of IL-2.  In activated T cells, the high affinity receptor is expressed and consists of 
all three chains, allowing activated T cells to respond to low levels of IL-2.  When IL-2 
binds its receptor, Janus kinases (Jak) are recruited and phosphorylate the IL-2 receptor, 
creating phosphorylated tyrosines that serve as docking sites for adaptor proteins such as 
Shc protein and STAT546, 47.  Shc activates the Ras-Raf-MAP kinase and P13 kinase/Akt 
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pathways leading to cytokine transcription, survival, and cell-cycle entry and growth.  
STAT5 translocates into the nucleus and acts as a transcription factor to upregulate 
expression of mitogenic and survival genes, like the anti-apoptotic Bcl-2 family members 
and the Pim family.     
The γ chain is shared by receptors for other cytokines, including IL-4, IL-7, IL-9, 
and IL-15, and activates the Jak/Stat and PI-3 kinase/Akt pathway mentioned above.  This 
redundancy suggests that other cytokines might also be effective for expanding T cells.  
Indeed, the results of several research groups reveal that other cytokines, notably IL-7 and 
IL-15, might be more effective for culturing tumor reactive T cells than the traditional IL-
248-50.  Like IL-2, both IL-7 and IL-15 have important roles in the homeostasis of T cells 47, 
50-52.  Homeostatic proliferation of naive T cells requires TCR contact with self 
ligand:MHC and stimulation from IL-7.  IL-7 promotes survival by inhibiting the 
mitochondrial pathway of apoptosis through the induction of Bcl-2 expression and by 
inhibiting nutrient withdrawal-induced apoptosis through the control of glucose uptake47.  
In excess, IL-2 and IL-15 can induce strong proliferation of naive T cells with a preference 
for CD8+ T cells.  Naive T cells that survive positive and negative selection and are 
maintained within the immune system become mature T cells and ultimately, memory and 
memory phenotype T cells.  Mature T cells are long-lived and maintained through 
continuous contact with self ligand:MHC and γ-chain cytokines, like IL-7 and IL-15. 
Resting memory phenotype cells are independent of MHC stimulation and have a 
heightened sensitivity to γ-chain cytokines.  Both IL-7 and IL-15 are important in 
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regulating background survival and turnover of memory phenotype CD8+ T cells and IL-7 
is important for CD4+ cells 50. 
IL-7 and IL-15 are important for the homeostasis of immunologically naive CD8+ 
T cells (CD44low) and memory phenotype T cells (CD44high).  Several primary sources 
have also noted the roles of these cytokines in the proliferation and survival of primed 
effector T cells (CD44high CD62low)49, 50, 53, 54.  A review by Boyman and colleagues noted 
that IL-2 is needed by CD8+ T cells for optimal in vitro expansion, survival at low cell 
densities, IFN-γ production, and cytotoxic function.  Because of the shared γ-chain motif, 
it is possible that IL-15 and IL-7 can supplement for IL-2 in stimulating primed CD8+ T 
cells.  The in vivo effect of IL-2, IL-7 and IL-15 on Ag-specific T cell proliferation were 
observed by injecting immunized mice with the cytokines and measuring T cell number 
and IFN-γ secretion in response to antigen 50.  Compared to IL-2, IL-7 and IL-15 were 
more potent in increasing the number of CD8+ effector and especially memory T cells 
specific for the tumor antigen.  IL-7 had a significant effect in prolonging the survival of 
tumor challenged mice when given in conjunction with immunization50.  At day 21, IL-7 
and IL-15 treated mice had a smaller tumor volume than IL-2 treated mice and survived 
longer than IL-2 treated mice, with IL-7 treated mice having the most prolonged lifespan.  
IL-15 at a dose of 50ng/ml is able to stimulate proliferation of tolerant and memory CD8+ 
T cells in vitro but not naive cells and selectively expands CD8+ T cells over CD4+ T cells 
in peripheral lymph nodes by augmenting cellular proliferation in vivo 49, 55.  The 
proliferation of tolerant CD8+ T cells in response to IL-15 is caused by a restoration of Ag 
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responsiveness, which allowed the lymphocytes to proliferate in response to tumor in vivo 
and prolong survival in all tumor bearing mice, leading to complete tumor regression in 
50% of AIT recipients49.  What is also interesting is that IL-15 seemed to be a better 
stimulator than IL-2 in their model.  IL-2 at physiologic or low doses (<100U/ml) did not 
stimulate proliferation of tolerant T cells and a dose of ≥1000U/ml was needed to mimic 
the response observed with 50ng/ml IL-15.  IL-2 also restores Ag responsiveness but in a 
smaller proportion of T cells and with blunted proliferation.  Klebanoff et al. compared T 
cells cultured in IL-2 versus IL-15 and found that the two cytokines induce phenotypically 
and functionally different populations of CD8+ T cells. IL-2 produces T cells with an 
effector memory phenotype (CD44high, CD62Llow, CCR7-, CD69+) while IL-15 produces 
central memory cells (CD44high, CD62Lhigh, CCR7+, CD69-)54, 56, 57.  Effector memory 
CD8+ T cells share similar phenotypic and functional properties as effector T cells and 
eventually become central memory cells that have enhanced sensitivity to antigen and the 
greatest potential for long term persistence in vivo57.  IL-2 and IL-15 cultured T cells 
secrete comparable levels of IFN-γ and TNF-α, but expressed different levels of IL-2 and 
IL-10 54.  Only IL-2 cultured T cells secrete IL-10, an immunosuppressive cytokine, and 
only IL-15 cultured cells secrete their own IL-2.  IL-15 cultured T cells also show much 
better in vivo expansion than IL-2.  IL-15 cultured T cells, when adoptively transferred 
were significantly better at improving survival of tumor bearing mice.  When given in 
conjunction with AIT, IL-15 helps prolong the resulting tumor regression and delays 
relapse longer than IL-256.  In lymphodepleted hosts, IL-7 and IL-15 are critical for the 
maintenance of CD8+ memory T cells53.  When anti-IL-7 antibody was used to deplete IL-
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7 in lymphodepleted hosts, a significant reduction in Ag-specific T cells was observed at 
the peak and contraction phases of T-cell expansion in response to antigen stimulation in 
vivo.  Although IL-15 knockout mice showed little difference in T cell numbers compared 
to controls, elimination of IL-15 in IL-7 depleted mice caused a greater reduction in T cell 
numbers.  These results demonstrate the need for IL-7 in the expansion and persistence of 
primed T cells in lymphodepleted mice after vaccination.     
Although IL-2 can promote T cell activation and proliferation, it also plays a 
pivotal role in the development of T regulatory cells and activation-induced cell death 
(AICD) of T cells.  These two effector functions of IL-2 may preclude it from being the 
optimal cytokine for T cell activation and expansion.  Activation-induced apoptosis is a 
FasL and IL-2 mediated pathway triggered by repeated antigen stimulation of primed T 
cells and is proposed to be a means of eliminating autoreactive T cells.  AICD is induced 
in WT T cells that are activated by antigen but not in naive T cells 58.  Apoptosis, increased 
FasL expression, increased FasL transcripts, and decreased FLIP transcripts are observed 
in activated IL-2-/- T cells when IL-2 is added but not in untreated cells.  These results 
definitively demonstrate the role of IL-2 in AICD and suggest that IL-2 functions as a 
transcriptional activator of FasL and an inhibitor of suppressors of FasL signaling (e.g. 
FLIP).  Research by Van Parijs et al. further elucidates the components of IL-2 signaling 
that lead to AICD59.  IL-2Rβ knockout cells were not sensitive to AICD and sensitivity 
was restored when cells were rescued with WT IL-2Rβ or a mutated form that prevents 
Shc binding and Akt activation (Y338F).  However, supplementing IL-2Rβ-/- cells with 
39 
 
forms of the receptor that cannot activate STAT5 (Δ355) failed to restore sensitivity.  
These cells also had lower FasL expression than IL-2Rβ-/- cells expressing WT or Y338F 
mutants, suggesting that STAT5 may be involved in AICD by decreasing FasL expression.  
The role of IL-2 in inducing AICD seems to rest on specific IL-2Rβ signaling motifs that 
involve STAT5 and eventually leads to the upregulation of FasL. While other cytokines, 
namely those that signal through the common γ, share signaling pathways with IL-2, AICD 
and regulation of autoreactive T cells seems to be unique to IL-2 in potency.  For example, 
IL-4 induction of proliferation does not seem to involve STAT5 and IL-4 does not inhibit 
FLIP58, 59.  Compared to IL-2, IL-15 given exogenously in addition to AIT has been shown 
to increase anti-apoptotic bcl-2, which is upregulated in memory lymphocytes and aids in 
their long term survival56.  IL-15 transgenic T cells expressing human IL-15 are resistant to 
AICD and this resistance is abolished when anti-IL-15 antibody is added55.       
Regulatory T cells (Treg) are suppressive cells that are important in the 
maintenance of peripheral tolerance by inhibiting T cells, B cells, dendritic cells, natural 
killer cells, and natural killer T cells.  They can be identified by the phenotype, 
CD4+CD25+(IL-2Rα)FOXP3+(forkhead box P3)46.   Increased Treg cells were observed 
in patients with various cancers, including non-small-cell lung cancer, ovarian, breast, 
colorectal, oesophageal, gastric, and lung.  A comprehensive review by Weiping Zou noted 
the correlation between reduced Treg numbers and reduced tumor volume when various 
Treg depleting techniques are employed60.  These regulatory cells differentiate in the 
thymus and traffic to tumour sites under the influence of CC-chemokine ligand 22 
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(CCL22) secreted by cancer cells.  Treg cells can also be converted from CD4+CD25- T 
cells by the tumor microenvironment.  There are multiple proposed immunosuppressive 
mechanisms employed by these cells.  Treg cells can induce the production of 
immunosuppressive molecules, like IL-10 from other lymphocytes.  IL-10 inhibits 
differentiation of T cells, secretion of cytokines, presentation of antigen, expression of 
costimulatory molecules, and dysregulation of cytolyic effector functions.  Competition for 
IL-2 and direct lysis of immune cells are other strategies used by Tregs to regulate the 
immune response.   
IL-2 is required for the induction of FOXP3, a definitive intracellular marker for 
Tregs that is also important for their development and function61, 62.  CD4+CD25+FOXP3+ 
T cells can be derived from human CD4+CD25+ and CD4+CD25- naive T cells after 
activation with anti-CD3 and anti-CD28 antibodies and exposure to high dose IL-2.  These 
cells suppress the proliferation of CD4+CD25- T cells and this inhibitory function 
correlates with the expression of FOXP361.  IL-2 also protects Tregs from apoptosis62.  
Mice that lack IL-2 develop lethal autoimmune disease that has been linked to a failure in 
Treg development, which can be restored by transfer of Tregs from WT mice or by 
treatment with IL-262.  Similarly, the development of Treg cells in patients with 
autoimmune hepatitis is impaired and can be restored by exposure to IL-261.  Although, the 
IL-2Rα chain has been implicated as the IL-2 receptor component that mediates IL-2 
induced Treg development, recent research suggest that the IL-2Rγ and its activation of 
STAT5 may be more important in regulating Treg cells62.  IL-7 and IL-15 have both been 
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shown to upregulate the expression of FOXP3 in CD4+CD25+ T cells and can maintain 
the suppressive potency of Tregs in vitro.  However, the concentration of IL-7 and IL-15 
needed to induce these effects were 20 to 50-fold higher than IL-2, respectively.  Thus, 
despite redundancy, IL-2 seems to be the primary cytokine involved in the ontogeny of 
Treg cells.  Although other cytokines can substitute for IL-2 in maintaining 
immunosuppression by Tregs, their potency is much less in comparison.   
Based on these findings, part of this thesis project investigates the combined 
effectiveness of IL-7 and IL-15 in culturing antigen specific T cells compared to the 
classical protocol using IL-2.   
Creating a Host Environment Conducive to AIT: Lymphodepletion 
 To optimize conditions for adoptively transferred T cells to persist and maintain 
effector functions in vivo, it is necessary to create a host environment more conducive to 
the success of AIT.  Two factors that hinder the success of AIT are competition from 
irrelevant lymphocytes for scarce resources and tumor-induced immunosuppression.   
Transferred T cells with tumor specificity make up only a small portion of the total 
lymphocyte population that resides in the host.  These irrelevant lymphocytes compete 
with tumor specific T cells for lymphoid space, antigens, and cytokines important in the 
promoting proliferation and persistence.  Lymphodepletion of the host before adoptive 
transfer is a technique that promotes the survival and function of effector T cells by 
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eliminating competition for limited resources.   A lymphopenic environment can be 
achieved through genetic manipulations, irradiation, and chemotherapy (e.g., 
cyclophosphamide).  Lymphodepletion of fibrosarcoma MCA tumor bearing hosts 
augments adoptive immunotherapy of pulmonary metastases, subcutaneous tumors, and 
intracranial tumors by reducing the T cell dose needed to completely eliminate metastases 
by 3-fold, 12-fold, and 4-fold, respectively48.  This better antitumor response is attributable 
to greater in vivo proliferation of effector cells at the tumor site in irradiated hosts 
compared to nonirradiated48, 53.  Enhanced proliferation of effector T cells may be caused 
by lymphodepletion-mediated  increase in the availability of cytokines and other 
homeostatic factors, increase in lymphoid space to which lymphocytes can traffick, 
decrease immunosuppression by Tregs, and/or induction of cytotoxicity to cancer cells.  
Unlike the fibrosarcoma MCA model, Gattinoni et al. found that in the BI6 melanoma 
model there was more of a qualitative than a quantitative difference in effector T cells 
adoptively transferred to irradiated and nonirradiated hosts63.  Pmel-1 T cells from 
lymphodepleted mice produced higher levels of IFN-γ, IL-2, granulocyte-macrophage 
colony stimulating factor, and TNF-α, and macrophage inflammatory protein-1α.  Through 
a set of subtle experiments, Gattinoni et al. establish cellular sink eradication as one of the 
key mechanisms underlying better success of AIT after lymphodepletion.   
Cyclophosphamide, an alkylating agent that mediates DNA crosslinking, may 
cause lymphodepletion in treated mice.  Experiments using cyclophosphamide (CYP) and 
AIT to treat Friend leukemia cells and RBL-5 melanoma cells resulted in complete tumor 
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regression in 100% of mice with no relapse for up to 100 days after treatment64.  The 
success with CYP and AIT mirror that of treatment with irradiation and AIT.  In these two 
models, CYP enhance AIT by inducing nonspecific proliferation of both naive and antigen 
specific T cells, upregulating a cytokine storm of GMCSF, IL-7 and IL-2 in the bone 
marrow and/or spleen of treated mice, and promoting antigen driven homing of transferred 
lymphocytes to secondary lymphoid organs.  Pretreatment with cyclophosphamide and 
fludarabine before AIT with autologous T cells and high dose IL-2 of patients with 
metastatic melanoma resulted in objective clinical responses in 6 out of 13 patients that 
manifested in the rapid growth of MART-1 specific T cells in vivo and tumor regression 65.   
Lymphodepletion may also abrogate the immunosuppressive effects of Tregs, 
which are recruited and stimulated by tumor cells.  In addition to the elimination of cellular 
sinks, the lymphopenic effect of CYP also helps reduce the number of Treg cells in tumor 
bearing animals and has been used in conjunction with AIT for that purpose66.  The 
mechanism by which CYP acts on Treg cells was elucidated by Lutsiak et al.67. When 
exposed to Tregs in culture, T cells from CYP treated mice showed 50%-70% greater 
proliferation than T cells from untreated mice.  Besides decreasing the immunosuppressive 
activity of Tregs, CYP also decreases Treg cell number in vivo by increasing sensitivity to 
apoptosis, decreasing proliferation, and downregulating expression of surface molecules 
like GITR and FoxP3 that are important in Treg function. 
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Creating a Host Environment Conducive to AIT: Targeting Myeloid Derived 
Suppressor Cells 
Although recognition of self antigens is desired in the adoptive immunotherapy of 
cancer, autoreactivity in normal circumstances results in severe autoimmune diseases, like 
Graves disease, Lupus, and Multiple Sclerosis.  The immune system has evolved special 
cell populations, like Treg cells, to prevent autoimmunity by lymphocytes that react 
strongly to self peptides.  In addition to Treg cells, autoimmunity is dampened by myeloid 
derived suppressor cells (MDSCs), a heterogenous population of immature cells of the 
myeloid/macrophage/dendritic cell lineage that has recently gained much attention in 
tumor immunology68-71.  MDSCs accumulate in tumor bearing hosts in bone marrow, 
blood, spleen, lymph nodes, and at the tumor site and are important in murine as well as 
human cancer progression.  For example, in patients with renal cell carcinoma(RCC), there 
is an upregulation of CD11b+CD14- MDSCs compared to healthy individuals (from ~10% 
in peripheral blood mononuclear cells to ~40% in RCC patients) 72.   In mice, MDSCs are 
identified by the phenotype CD11b+Gr1+ and also express CD31, CD124, IL-4Rα, 
CD115, and MCSF-R.  MDSCs that have been identified in humans have the phenotype: 
Lin-, CD14-, HLA-DR-, CD15+, CD34+, CD11b+, CD33+, and CD13+69, 72-74.  
Accumulation of MDSCs is caused by the tumor microenvironment through secreted 
factors that stimulate myelopoiesis (e.g., granulocyte/macrophage colony stimulating 
factor, Flt3, monocyte CSF, and IL-3) and prevent differentiation of immature myeloid 
suppressor cells (e.g., vascular endothelial growth factor)70.  In vitro studies have shown 
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that MDSCs also secrete autocrine factors that drive their maturation and differentiation.  
The maturation/differentiation of MDSCs is correlated with increased suppressive function 
so that MDSCs found circulating in the blood or in the spleen are less potent than tumor 
infiltrating MDSCs, which are more mature and have constitutively activated arginase-1 
(ARG-1) and nitric oxide synthease (NOS-2)70.   CD11b+ splenocytes from tumor bearing 
mice but not naive mice produce IFN-γ, a Th1 cytokine, and IL-13, a Th2 cytokine.  IFN-γ, 
from activated CD8+ T cells and MDSCs, as well as IL-13 are needed for the full 
activation of MDSC effector activity.  MDSC production of reactive oxygen species also 
maintains their undifferentiated status and promotes proliferation75.     
MDSCs reduce antigen specific CD8+ T cell proliferation, increase T cell death by 
apoptosis, foster T cell tolerance, and change the profile of cytokines secreted by activated 
T lymphocytes70, 72, 74, 76.  They exert their immunosuppressive effects primarily through 
the secretion of arginase-1 (ARG-1) and nitric oxide synthase (NOS2).  ARG-1 causes the 
depletion of L-arginine in the local environment and leads to the production of urea and 
ornithine 70.  L-arginine starvation and increased urea concentrations impair translation and 
is correlated with the downregulation of CD3ζ expression and IL-2 and IFN-γ production.  
NOS2 catalyzes the reaction between O2 and L-arginine to generate L-citrulline and nitric 
oxide (NO), which inhibit intracellular signaling pathways needed for T cell proliferation 
and survival and favors apoptotic signaling.  In the absence of L-arginine, superoxide 
anion (O2-) is generated and reacts with other molecules to create reactive nitrogen oxide 
and reactive oxygen species that cause biological damage.  Of note, O2- and NO react to 
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form peroxynitrite (ONOO-), which modifies proteins through oxidation and nitration of 
amino acids.  
ARG-1 and NOS2 have a myriad of inhibitory effects on T cells72, 73, 75, 77.  
Arginase activity is upregulated in renal cell carcinoma patients along with MDSC 
accumulation.  This is accompanied by a decrease in CD3ξ  expression on T cells, a 
decrease in L-arginine levels, a decrease  in activated T cell production of IL-2, IFN-γ, IL-
4, and IL-10, and an increase in L-ornithine levels72.  This decrease in IFN-γ production in 
humans contrast with results in mice, where MDSCs inhibit proliferation but not IFN-γ 
secretion70, 75.  The role of IFN-γ in promoting or inhibiting MDSC activity also varies70, 77, 
78.  Suppression of T cells by MDSCs seems to be both specific and nonspecific and can 
occur during both the early and late stages of T cell activation 76, 79, 80.  MDSCs inhibit the 
early stage of T cell activation, MHC:Ag binding, by inducing Ag-specific MHC class I-
restricted tolerance79.  When MDSCs are present in vivo, CD8+ T cells do not bind MHC 
and do not secrete IFN-γ in response to specific peptide.  It is hypothesized that this 
nonresponsiveness is the result of MDSC generation of reactive oxygen species (ROS) and 
peroxynitrite (ONOO-), which modifies TCR and CD8 molecules.  MDSCs from mice that 
cannot produce ROS (gp91phox-/-) did not induce T cell tolerance, and treatment with uric 
acid, which specifically neutralizes ONOO-, rescues tolerant T cells.  Through the nitration 
of tyrosines in the MHC-TCR complex, ONOO- induces a rigidity that interferes with 
TCR-MHC interaction.  Culture with functional MDSCs increases nitrotyrosine in CD8+ T 
cells, which is not seen when T cells are cultured with MDSCs from gp91phox-/- or iNOS-/- 
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mice.  Kusmartsev et al. argues that MDSC suppression of T cells is Ag specific and MHC 
class I dependent in a different manner 78.  They found that inhibition of CD8+ T cell 
responsiveness is mediated by MDSC production of ROS.  Activation of ROS production 
by MDSCs is caused by stimulation of adhesion molecules that are upregulated in MDSCs 
from tumor-bearing mice and requires stable interaction fostered by Ag specific T cells but 
not naive T cells. 
MDSCs also suppresses T cells during the late stage of activation at the level of IL-
2R signaling76.   T cell proliferation stimulated by both mitogenic factors and Ag specific 
activation is blocked by MDSCs that prevent the lymphocytes from entering the cell cycle.  
This inhibition is reversible and is caused by impaired IL-2R signaling pathways 
(JAK/STAT, RAS/MAPk, and P13k/Akt).  Even in the presence of excess IL-2 and 
mitogenic factors, phosphorylation of STAT5, ERK1/2 and Akt is absent.  NO is believed 
to mediate this late suppression.  Addition of NO to T cell cultures inhibited mitogen 
stimulated proliferation and phosphorylation of JAKs and STATs and inhibition of NOS 
reversed MDSC mediated inhibition of proliferation.   
The expression of ARG-1 and NOS2 is stimulated by cyclooxygenase-2 (cox2), 
which is overexpressed in most human cancers.  In addition, IFN-γ has been shown to 
increase NOS2 mRNA and protein levels in a dose dependent manner and IL-13 
upregulates ARG-1 mRNA and protein concentrations70, 76.  Both cytokines are believed to 
work in an additive manner to activate fully the suppressive arms of MDSCs.  Inhibition of 
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either cytokine suppresses MDSC function.  Kusmartzev et al. demonstrated that STAT1, 
but not STAT3 or STAT6, is involved in the signaling pathway that mediates MDSC 
suppression of T cells73.  MDSCs from STAT1 knockout mice do not suppress T cell 
responses and lack ARG-1 activity and NOS-2 expression and NO production. These 
results implicate the Jak/Stat signaling pathway in the regulation of tumor immunity 
through modulation of MDSC function. 
In addition to direct inhibition of T cells through ARG-1 and NOS2 production, 
MDSCs also mediate indirect mechanisms of inhibition that are independent of these 
enzymes.  Sinha et al. demonstrate cell contact dependent cross talk between MDSCs and 
macrophages that resulted in increased IL-12 production by macrophages and increased 
IL-10 production by MDSCs81.  This skews T cell immunity from one that promotes tumor 
rejection (Th1) to one that favors tumor progression (Th2) by driving the development of 
M2 macrophages (IL-12low, IL-10high) over M1 macrophages (IL-12high, IL-10low) that 
promote CD8+ T cell differentiation and decrease MDSC numbers 77, 82.  In addition, IL-10 
inhibits dendritic cell maturation.  Both dendritic cells and macrophages play important 
roles in antigen presentation and secrete factors that promote the development of cellular 
immunity.    
The lack of consensus on the specific mechanisms by which MDSCs exert their 
immunosuppressive effects on T cells suggests the existence of different subsets of 
MDSCs with diverse inhibitory functions.   These MDSCs present a barrier to cellular 
immunity and abrogation of their influence may increase the likelihood of successful AIT.  
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Depletion of MDSCs in mice augments AIT and depletion of CD11b+ MDSCs in RCC 
patients increases proliferation, IFN-γ secretion, and CD3ζ expression in peripheral blood 
mononuclear cells70, 72 .  Several methods have been developed to inhibit MDSCs.  Anti-
Gr-1/Ly6G antibody has been used to deplete MDSCS, but because this marker is also 
expressed on neutrophils, use of this antibody may lead to severe immunosuppression71, 83. 
Blocking ONOO- with uric acid has been shown to prevent T cell tolerance in tumor 
bearing mice and to delay tumor growth79.  Blocking the products of MDSCs, through uric 
acid or ARG-1 and NOS2 inhibitors, however, does not inhibit the known and unknown 
immunosuppressive mechanisms that rely on cell-cell contact.  Thus, it may be more 
effective to directly eliminate MDSCs in tumor bearing hosts.  One way to do this is to 
stimulate differentiation of MDSCs into dendritic cells using IL-4 and all-trans retinoic 
acid80.  Another method that has attracted attention because of its ease of application is a 
chemotherapy drug called gemcitabine (GEM), which was first shown to deplete MDSCs 
by Suzuki et al. in 200585.  GEM given to animals bearing large TC-1 tumors (1000mm3) 
reduced splenic MDSCs from 28.5% in control mice to 9.3% in treated mice while leaving 
important CD4+ T cell, CD8+ T cell, and B cell populations unperturbed.  MDSC 
immunosuppression of T cells is also reduced by GEM.  CD8+ T cells given in 
conjunction with splenocytes from GEM treated animals and TC-1 tumor cells 
significantly inhibited tumor development compared to combination with splenocytes from 
untreated mice.  GEM has also been shown to slow the growth of primary tumors and 
decrease MDSC proportion in the blood of tumor bearing mice81.  These results prompted 
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the question: does GEM act directly on MDSCs or does direct anti-tumor effect decrease 
tumor-load and thereby decrease MDSCs indirectly? 
Gemcitabine or 2’,2’-difluorodeoxycytidine is a pyrimidine antimetabolite that has 
been used clinically to treat patients with non-small-cell lung cancer, ovarian cancer, and 
breast cancer86.  This antimetabolite works during the S phase of the cell cycle and  
requires phosphorylation to become active; it is phosphorylated by deoxycytidine kinase, 
deoxycytidine monophosphate kinase, and nucleoside diphosphate kinase to 
difluorodeoxycytidine monophosphate, difluorodeoxycytidine diphosphate, and 
difluorodeoxycytidine triphosphate.  The triphosphate form inhibits DNA synthesis by 
competitive inhibition of DNA polymerase and by incorporation into DNA and is believed 
to have a tumoricidal effect by inducing apoptosis caused by early termination of DNA 
synthesis.  The diphosphate form inhibits ribonucleotide reductase and thereby reduces the 
pools of deoxyribonucleotides available for DNA synthesis.  The advantage of using GEM 
is that it is already approved by the Food and Drug Administration to treat metastatic 
cancer and is well tolerated in patients.  Although GEM has been associated with 
myelosuppression, it has not been applied clinically as an agent to abrogate the 
immunosuppression caused by MDSCs.  The second part of this thesis explores the 
application of GEM to determine how MDSCs mediated escape from antitumor immunity 
can be reversed.  We believe that combating MDSCs using gemcitabine as a therapeutic 
intervention will greatly aid AIT.     
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{CHAPTER 3 B/I Activated DLN Cells Cultured with IL-7/15 
Show Greater Expansion in vitro than Cells Cultured with IL-2 
and Demonstrate in vivo Antitumor Reactivity } 
 
Introduction 
 Adoptive immunotherapy (AIT) relies, at least in part, on the ability to 
produce large numbers of tumor specific lymphocytes.  Our lab has developed a protocol 
for effective activation and expansion of draining lymph node (DLN) cells harvested from 
tumor bearing animals, using bryostatin-1 (B) and ionomycin (I).  Bryostatin-1 activates 
protein kinase C and has been shown to induce the expression of IL-2Rα on human CD4+ 
and CD8+ lymphocytes87.  Ionomycin is a calcium ionophore that in conjunction with 
bryostatin-1 induces IL-2 expression and secretion and augments proliferation of T cells41, 
87.  Together the two mimic signaling pathways activated by antigen:MHC stimulation of 
the T cell receptor.  Stimulation with B/I caused 2-3x greater proliferation than in vitro 
stimulation with autologous tumor cells and caused the number of T cells to increase from 
40% to 100% after B/I + IL-2 stimulation35, 43, 44.   B/I was selective in its mode of action, 
preferentially activating antigen sensitized T cells, but not naive lymphocytes36, 42-44.  The 
effectiveness of these agents was apparent in both murine and human DLN cells.  DLNs 
from breast cancer patients expanded 269-28,206-fold in IL-2 after exposure to B/I42.  B/I 
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expanded DLN cells trafficked to tumor sites and exerted tumor specific cytotoxicity35, 36.  
In combination with partial lymphodepletion induced by cyclophosphamide treatment, B/I 
expanded T cells were able to cause complete regression of lung metastases, liver 
metastases, and intradermal tumors and protected cured hosts from tumor challenge36, 88.   
Despite the efficacy of this B/I regimen, bryostatin-1 was toxic to DLN cells, 
inducing apoptosis in 84% of the cells by inhibiting interleukin-2 (IL-2) secretion89.  
Administration of IL-2 protected against B/I induced cell death, but about half the DLN 
cells still died.  The upregulation of cell death in the absence of IL-2 demonstrates the 
important role cytokines played in the persistence and function of T cells.  IL-2 is a key 
cytokine in the expansion and survival of T cells and promotes cytokine production in 
activated lymphocytes.  For these reasons, IL-2 has been the standard cytokine used for T 
cell expansion in murine models and in the clinic13, 14, 22, 24, 29, 35, 36, 43.   However, other γ 
chain cytokines may be more efficient for this purpose.  While IL-2 promotes growth and 
development of predominantly effector T cells, IL-7 and IL-15 generate central memory T 
cells, which may be more effective in adoptive immunotherapy, since memory 
lymphocytes can persist long-term and require lower antigen doses and less costimulation 
to mount a rapid and potent immune response.  This was demonstrated when OT-1 T cells 
were rechallenged with OVA peptides after culture with IL-2, IL-7 or IL-1557.  IL-7 and 
IL-15 cultured T cells, which expressed a central memory phenotype, responded with 
strong proliferation and IFN-γ secretion when rechallenged with OVA peptide57, 90.  
However, T cells cultured with IL-2 did not proliferate when re-exposed to Ag but 
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underwent activation induced cell death(AICD)  instead.  AICD is mediated by IL-2 upon 
restimulation of the TCR of previously activated T cells, which is undesirable for the 
purposes of AIT.  In addition, IL-2 is crucial in the development of T regulatory (Treg) 
cells, which maintain peripheral tolerance by inhibiting other lymphocytes and can inhibit 
anti-tumor immunity.  While other STAT5 activating cytokines can substitute for the 
absence of IL-2, they are much less important in this process46, 61, 62.  
The induction of AICD and T regulatory cells by IL-2 prompted us to explore other 
cytokines for use in T cell expansion.  Because IL-2 belongs to a subset of interleukins that 
share signaling pathways mediated by the common γ chain, our investigation began with 
cytokines that share that receptor, namely IL-7 and IL-15.  Both IL-7 and IL-15 regulate 
homeostatic proliferation of T cells and protect against apoptosis47, 50-52.  However, the two 
cytokines have slightly different functions.  IL-7 maintains both naive and memory T cells 
and protects against apoptosis by 1) increasing bcl-2 expression and 2) controling glucose 
uptake to prevent apoptosis caused by nutrient withdrawal47.  IL-15 acts primarily on 
memory T cells and protects against IL-2 induced AICD55, 56.  Both IL-7 and IL-15 have 
demonstrated the ability to reverse tolerance in T cells from tumor bearing mice and drive 
the expansion of effector and memory lymphocytes 49, 53, 54.  Mechionda et al. showed that 
IL-7 and IL-15 were comparable or better than IL-2 at expanding Ag sensitized T cells 
when given as an adjuvant in vivo along with immunization 50.  However, it seems that in 
vitro, IL-2 induced more tumor responsive T-cells with a greater capacity to proliferate in 
comparison to either IL-7 or IL-15 alone 57.  This contrasted our preliminary data, in which 
IL-15 induced >2-fold higher expansion of activated T cells than IL-2 and IL-7 induced 2-
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3-fold greater expansion.  The difference in cytokine activity might be due to our use of 
B/I to activate sensitized T cells.  Observation of IL-15 and IL-7 knockout mice revealed 
that IL-15 is required to maintain the complete functionality of CD8+ T cells but not the 
number and conversely, IL-7 maintains proliferation and survival, but not the function of 
adoptively transferred cells63.   Knockout of both cytokines impaired both quantity and 
quality of CD8+ T cells.  Because IL-7 and IL-15 given individually was not drastically 
more effective than IL-2 and because the two complement each other in qualitative and 
quantitative function, we aimed to investigate the combined effects of IL-7 and IL-15 on T 
cell expansion to drive the development of potent antitumor T lymphocytes. 
Materials and Methods 
Mice 
Virus-free C57Bl/6 (National Cancer Institute) and female pmel-1 TCR transgenic 
mice (bred in-house) were used between 8 and 12 weeks of age.  Animals were caged in 
groups of 6 or fewer and provided food and water ad libitum. All guidelines of the Virginia 
Commonwealth University Institutional Animal Care and Use Committee, which conform 
to the American Association for Accreditation of Laboratory Animal Care and the U.S. 
Department of Agriculture recommendations for the care and humane experimental use of 
animals, were followed. 
Tumor Cell Lines 
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B16-GMCSF and B16-F10 melanoma tumor cell lines and were kindly provided by 
Dr. Richard Dutton at the Trudeau Institute, Saranac Lake, NY. and Dr. Rodney Prell at 
Cell Genesys, Inc., South San Francisco, California. After thawing from storage in liquid 
nitrogen, B16-GMCSF cells were cultured in complete Dulbecco’s Modified Essential 
Medium (DMEM) with 10% heat-inactivated fetal calf serum (Hyclone, Logan, UT), 1mM 
sodium pyruvate (Mediatech, Inc, Herndon, VA) , 100 U/ml penicillin (Invitrogen, Grand 
Island, NY), 100 ug/ml streptomycin, 0.075% sodium bicarbonate, and 10mM HEPES 
buffer.  B16F10 melanoma cells were cultured in complete RPMI 1640 with 10% heat-
inactivated fetal calf serum, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 
0.075% sodium bicarbonate, 2mM L-glutamine, 100 U/ml penicillin, 100 μg/ml 
streptomycin, 10 mM Hepes buffer, and 5×10-5M 2-mercaptoethanol (Sigma, St. Louis, 
MO).  Tumor cells were harvested for inoculation of mice with 0.05% trypsin-EDTA 
(Invitrogen), washed twice with 1xPBS and resuspended in 1xPBS. All cells were 
incubated in 250 ml T-flasks (PGC, Gaithersburg, MD) at 37oC in humidified air with 5% 
CO2. 
Draining Lymph Node (DLN) Sensitization and Harvest 
 Donor pmel-1 mice were injected with 1x106 B16-GMCSF cells in the footpad.  
Ten days after inoculation of footpads, mice were sacrificed and ipsilateral popliteal 
draining lymph nodes were harvested into complete RPMI using sterile technique.  DLNs 
were crushed through a metal screen and single cell suspensions were prepared in complete 
RPMI. 
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In vitro Activation of DLN Cells and Expansion 
 DLN cells were brought to a concentration of 1x106 cells/ml activated by 
incubation with 5 nM bryostatin-1 (provided by the National Cancer Institute, 
Bethesda, MD), 1 uM ionomycin (Calbiochem, San Diego, CA) (B/I), and 80U/ml of 
rIL-2 (Chiron, Emeryville, CA) or 10ng/ml each of IL-7/15 (Peprotech Inc, Rocky Hill, 
NJ)  in 50ml conical polystyrene tubes at 37°C, 5% CO2, for 18 hours.  Cells were washed 
three times with warm complete RPMI and resuspended at 1x106 cells/ml.  DLN cells were 
expanded in complete RPMI supplemented with an additional 5% heat-inactivated fetal 
calf serum with either 40U/ml of rIL-2 or 10ng/ml each of IL-7 and IL-15.  The cells were 
allowed to proliferate in culture for an additional 7-9 days and were split every 2-3 days in 
order to maintain 1x106 cells/ml concentration.   
Adoptive Immunotherapy 
Host C57Bl/6 mice were inoculated intravenously (IV) with 250,000 B16-F10 
melanoma cells and randomized into different treatment groups: a) untreated control b) 
cyclophosphamide (CYP) only c) CYP + AIT with various doses of lymphocytes.  On day 
3, mice were pretreated with intraperitoneal (IP) injection of 100mg/kg CYP (Bristol-
Myers Squibb Company, Princeton, NJ). On day 4, the B/I activated and expanded DLN 
lymphocytes were washed twice in serum free medium (RPMI 1640) and injected 
intravenously into host mice at a dose of 2x106, 7.5x106, or 15x106.  After 24 days, mice 
were sacrificed and lungs were harvested and placed in Fekete’s Solution (85% ethanol, 
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10% formaldehyde, and 5% acetic acid).  Metastases form black nodules and were counted 
using a dissecting light microscope.  Mice with metastases too numerous to count were 
assigned an arbitrary value of 250 because this is the largest number of nodules that could 
be reliably enumerated per mouse.  Data are shown as mean number of metastases ± 
standard error (SE) with 6 mice/group. 
 
Phenotype Assay 
 Cells were brought to 1x106 cells/ml in 100ul and stained for 30 minutes with anti-
mouse, PE-conjugated anti-CD4-mAb, anti-CD8-mAb, anti-CD62L-mAb, anti-CD44-
mAb, and anti-CD69-mAb (BD Pharmingen, San Diego, CA). Unstained cells were used 
as the negative control. Rat IgG2b,κ was used as the isotype control for CD4 and CD44, rat 
IgG2a,κ  for CD8 and CD62L, and Hamster IgG1, κ for CD69.  Stained cells were fixed 
with 2% paraformaldehyde and analyzed within 7 days of staining on an ELITE Beckman 
Coulter flow cytometer. 15,000 cells per sample were analyzed. 
Interferon γ release assay 
 
Antigen sensitized, B/I activated T-cells that had been cultured in IL-2 or IL-7/15 
were assayed for IFN-γ secretion in response to specific and nonspecific antigen.  The 
lymphocytes were cultured in 24-well plates at 2x106 cells/ml with either no stimulants, 
irradiated (10,000 rads) spleen cells (negative control), or irradiated spleen cells pulsed 
with GP100 peptide (KVPRNQDWL).  Lymphocyte to stimulator ratio was 10:1. After 24 
hours of culture, supernatant was harvested and stored at -20°C until assayed using a 
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murine IFN-γ ELISA kit (BD Biosciences Pharmingen, San Diego, CA). Results reported 
are the mean values of duplicate ELISA wells ± SD. 
Apoptosis Assay 
 Apoptosis was determined using the standard Annexin V-FITC Apoptosis 
Detection kit (BD Biosciences Pharmingen, San Diego, CA).  B/I activated and expanded 
DLN cells were washed twice with 1xPBS and resuspended in 1x binding buffer at a 
200,000 cells/100ul and double stained for Annexin V and propidium iodide (PI).  
Unstained cells were used as negative controls and staining with Annexin V alone or PI 
alone was used as single color positive controls. 20,000 cells per sample were analyzed.  
 
Statistical analysis  
 
Differences in pulmonary metastases were assessed by analysis of variance 
(Wilcoxon-Rank Sum Test) using JMPIN software (SAS Institute Inc., Cary, N.C.). 
Results are presented as the means ± standard error (SE) in each treatment group. In vivo 
experiments included six mice per group.  In vitro assays were repeated as indicated. An α 
< 0.05 was used throughout to determine significant differences. 
 
Results 
IL-7/15 Supports Greater Expansion of B/I Activated DLN Cells than IL-2 
 Preliminary data showed that IL-7 and IL-15 expanded B/I activated DLN cells 2-
3-fold and 5-fold better than IL-2, respectively.  Thus, we were curious to see whether or 
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not there would be an additive or synergistic effect when the two cytokines were 
combined.  Pmel-1 mice were injected with 1x106 B16-GMCSF cells in the footpad.  Ten 
days later ipsilateral popliteal DLNs were harvested and pulsed for 18hr at 1x106 DLN 
cells/ml in bryostatin-1(5nM)/ionomycin(1uM) (B/I) + IL-2 (80U/ml) or B/I + IL-7/15 
(10ng/ml each) then expanded in either IL-2 (40U/ml) or IL-7/15 (10ng/ml each). After six 
days of expansion, B/I activated DLN cells cultured in IL-7/15 showed greater expansion 
than IL-2 expanded cells (Fig. 2).  IL-7/15 cultures showed a total of 44-fold increase in 
cell number compared to a 7.6-fold increase in IL-2 cultures (Fig. 2A).  This was a 479% 
increase.  At the end of nine days, there was a 757% difference in fold expansion between 
IL-7/15 and IL-2 cultures.  In addition, while IL-2 cultured DLN cells reached a peak at 
around day 6 and began to decline in numbers, IL-7/15 DLN cells continued to proliferate 
until day 9 of culture and beyond.  A repeat of the experiment verify a >400% difference in 
expansion between IL-7/15 and IL-2 cultures by day 6 and this difference in expansion did 
not depend on the cytokine regimen used in the B/I pulse step (Fig. 2B).     
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{Figure 2: IL-7/15 induces 8-9 fold greater growth of DLN cells than IL-2.}  
(A) Pmel-1 mice were injected with 1x106 B16-GMCSF cells in the footpad.  Ten days 
later ipsilateral popliteal DLNs were harvested and pulsed for 18hr at 1x106 cells/ml in 
B(5nM)/I(1uM) + IL-2 (80U/ml) or B/I + IL-7/15 (10ng/ml each) then expanded in IL-2 
(40U/ml) or IL-7/15 (10ng/ml each), respectively, for 9 days.   
(B) DLN cellss were harvested and brought to 1x106 DLN cells/ml.  The cells were 
divided into two pulse conditions.  Cells were either pulsed with B(5nM)/I(1uM) + IL-2 
(80U/ml) or B/I + IL-7/15 (10ng/ml each) for 18hr.  Each pulse group was then divided 
into two cultures so that one received IL-2 (40U/ml) and the other IL-7/15 (10ng/ml each).    
61 
 
 
Greater Expansion by IL-7/15 was Partly due to Protection against Apoptosis 
 IL-2 has been associated with activation induced cell death (AICD) of T 
lymphocytes while IL-7 and IL-15 are known promoters of survival, protecting against 
apoptosis induced by nutrient starvation and AICD.  Because there was such a significant 
difference in expansion when B/I activated DLN cells were cultured in IL-7/15 compared 
to IL-2, we wondered whether or not there was a difference in the rate of apoptosis 
between the two culture conditions.  Samples of B/I activated DLN cells were taken at 
various time points during culture and stained with annexin V and propidium iodide (PI).  
Cells that only stained for PI were necrotic or dead.  Those that only stained for annexin V 
were in early apoptosis and cells that stained for both were in late apoptosis (Fig. 3).  On 
day 3 of expansion, B/I activated DLN cells in IL-2 and IL-7/15 cultures showed similar 
rates of apoptosis (15.5% and 16.5%, respectively).  However, by day 6, there was a 
significant difference in proportion of cells undergoing apoptosis.  The IL-7/15 cultured 
cells were 80.9% viable cells and 18.4% apoptotic (early + late) cells, compared to 57.7% 
viable cells and 40.2% apoptotic cells in the IL-2 culture.  This was a 40% increase in 
viability and a 54.2% decrease in the apoptotic rate.  The difference in the rate of apoptosis 
remained at day 8 of expansion and contributed to the differences in the observed cell 
numbers.   
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{Figure 3: IL-7/15 expanded B/I activated DLN cells have a smaller proportion of 
apoptotic cells than IL-2 expanded cultures.}  
B16-GMCSF sensitized DLNs from pmel-1 mice were harvested and pulsed for 18hr at 
1x106 DLN cells/ml in B(5nM)/I(1uM) + IL-2 (80U/ml) or B/I + IL-7/15 (10ng/ml each) 
then expanded in IL-2 (40U/ml) or IL-7/15 (10ng/ml each), respectively. Samples were 
taken on days 3, 6 and 8 of expansion and stained for Annexin V-FITC and propidium 
iodide (PI).  Fluorescence of at least 20,000 cells per sample was analyzed by flow 
cytometry.  The differences in apoptosis between IL-2 and IL-7/15 cultures are 
representative of three independent experiments. 
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IL-7/15 Induces Similar Subsets of T cells as IL-2 and Maintains Central Memory CD8+ T 
Cells Better than IL-2 
An earlier experiment in the Bear lab showed that induction of tumor regression by 
adoptive transfer of B/I activated cells is dependent on CD8+ T cells88.  We next 
questioned whether or not IL-7/15 maintained similar CD8+ T cells subsets as IL-2.  B/I 
activated DLN cell cultures were sampled and cell surface phenotypes were determined by 
immunofluorescence staining using monoclonal antibodies against CD4, CD8, CD44, 
CD62L and CD69 (Table 1).  CD4 is a marker for helper T cells, CD8 is a marker for 
cytotoxic T cells, CD44 is a marker for T cells with the memory phenotype and CD69 is a 
marker for activated T cells.  CD62L (or L-selectin) is a lymph node homing molecule that 
is downregulated upon T cell activation in association with an increase in T cell effector 
function.   As T cells transition to the central memory phenotype CD62L expression is 
increased.  On days 1 and 3, when DLN cells were on the upward part of their growth 
curves, IL-7/15 and IL-2 expanded DLN cells showed similar proportions of activated 
CD4+ and CD8+ T cells.  Compared to fresh DLN cells, expanded DLN cells increased the 
proportion of activated T cells by day 1, indicated by a decrease in CD62L expression and 
an increase in CD69 expression. CD69 expression is decreased as expected after day 1.  By 
day 3 of expansion, there was an increase in the CD8+ population in both cultures and an 
increase in T cells with the memory phenotype.  By day 7, when IL-2 cultured cells have 
begun to decline in numbers, there was a shift in the CD4+ and CD8+ populations 
compared to IL-7/15 cultured cells.  Specifically, there was an increase in the CD4+ subset 
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in IL-2 cultures and a decline in the CD8+ and CD44+ subsets.  In contrast, IL-7/15 
cultures maintained high proportions of CD8+ and CD44+ cells with no change in the 
CD4+ subset.   There also seemed to be a shift in IL-7/15 cultures from an effector 
memory (CD44highCD62Llow) to a higher proportion of central memory phenotype 
(CD44highCD62Lhigh) while IL-2 cultures maintained an effector phenotype.  Although the 
results were not definitive, they indicate that IL-7/15 was able to maintain equal or greater 
proportions of activated CD4+ and CD8+ T cells when compared to IL-2 and favored the 
induction of central memory CD8+ T cells over time.  Both expansion regimens enriched 
for T cells so that the DLN pool, which was about 50% or less T cells when freshly 
harvested, was composed of 100% T cells by day 7 of culture.  In addition, Figure 2B + 4 
and Table 1 show that the proliferation, phenotype, and antitumor response of DLN cells 
depended on the cytokines used for expansion and did not depend on what cytokine 
regimen was used during pulsing with B/I.   
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Table 1: IL-7/15 expands similar T cell subsets as IL-2 and maintains central memory 
CD8+ T cells better than IL-2.   
B16-GMCSF sensitized DLNs were harvested from pmel-1 mice and pulsed for 18hr at 
1x106 DLN cells/ml in B(5nM)/I(1uM) + IL-2 (80U/ml) or B/I + IL-7/15 (10ng/ml each) 
then expanded in either IL-2 (40U/ml) or IL-7/15 (10ng/ml each). Samples were taken on 
days 1, 3 and 7 of expansion and incubated with mAb against CD4, CD8, CD44, CD62L, 
and CD69. Fluorescence of 15,000 cells per sample was analyzed by flow cytometry.  
Numbers represent percentage of cells with the indicated phenotype. 
 
  CD4 CD8 CD44 CD62L CD69 
Pre-pulse  7.30 34.6 58.7 72.5 13.1 
DAY 1 B/I + IL-2  IL-2 3.79 42.0 72.6 46.0 50.4 
B/I + IL-2  IL-7/15 4.96 35.1 74.5 52.1 60.0 
B/I + IL-7/15  IL-2 5.13 44.4 79.1 51.1 65.7 
B/I + IL-7/15  IL-7/15 6.05 36.2 76.8 53.3 67.2 
DAY 3 B/I + IL-2  IL-2 9.93 75.6 86.2 32.7 14.1 
B/I + IL-2  IL-7/15 6.29 80.0 91.3 57.1 13.1 
B/I + IL-7/15  IL-2 11.6 74.0 90.2 43.0 27.7 
B/I + IL-7/15  IL-7/15 6.94 87.3 95.2 69.7 43.8 
DAY 7 B/I + IL-2  IL-2 27.0 52.8 -- 33.8 15.1 
B/I + IL-2  IL-7/15 6.06 94.3 87.7 71.7 43.4 
B/I + IL-7/15  IL-2 24.9 56.9 59.8 27.0 6.14 
B/I + IL-7/15  IL-7/15 6.61 93.4 93.7 60.5 35.0 
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IL-7/15 Expanded B/I activated DLN Cells Respond Specifically to Tumor Antigen 
 Our lab has shown that IFN-γ secretion plays a key role in tumor regression 
mediated by CD8+ DLN cells and is therefore used as a marker for antitumor reactivity 91.  
To compare the tumor response of IL-2 and IL-7/15 expanded DLN cells, we stimulated 
expanded cells with plain media (negative control), irradiated splenocytes (negative 
control), or the gp100 peptide.  The gp100 peptide, KVPRNQDWL, is a differentiation 
antigen upregulated on melanoma cells and is the cognate epitope for the transgenic TCR 
of pmel-1 mice.  This peptide was used to assay the antigen specific reactivity of DLN 
cells that were sensitized to B16-GMCSF melanoma.  After 24 hours, supernatant was 
collected and IFN-γ levels were measured (Fig. 4).  Pre-expansion cultures that have not 
yet been expanded showed reactivity to gp100 as expected, but not to media alone or to the 
negative control (Fig. 4A).  Specificity to gp100 but not to irradiated spleen was 
maintained throughout expansion for all cultures (Fig. 4A-D).  Interestingly, DLN cells 
expanded in IL-2 started with potent reactivity to gp100 on day 1, with high levels of IFN-
γ secretion but showed a decrease in antitumor response over time.  In contrast, IL-7/15 
cultured cells had minimal antitumor response on Day 1 of expansion but increased IFN-γ 
secretion in response to gp100 over time so that by day 3, the concentration of INF-γ 
secreted by IL-7/15 expanded cells was similar to that of IL-2 expanded cells on Day 1 and 
surpassed the declining response of IL-2 cultured cells.  This high response to gp100 by 
IL-7/15 expanded cells increased further by day 7 of expansion, when IL-2 expanded cells 
showed a flat or even declining IFN-γ response.  Because IFN-γ is a product of activated T 
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cells, the change in the production of this cytokine in IL-2 cultures in response to specific 
peptide may reflect the decline in proportion of CD8+ T cells over time (Table 1).  
Similarly, the maintenance of high antitumor responses by IL-7/15 expanded T cells on 
Day 3 and 7 may reflect the maintenance of a large, viable and functional CD8+ T cell 
population in IL-7/15 cultures (Table 1).    
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Figure 4. IL-7/15 expanded DLN cells show an increase in IFN-γ secretion in response 
to specific antigen while IL-2 expanded DLN cells decline in reactivity over the course 
of ex vivo culture. 
B16-GMCSF sensitized DLNs from pmel-1 mice were harvested and pulsed for 18hr at 
1x106 DLN cells/ml in B(5nM)/I(1uM) + IL-2 (80U/ml) or B/I + IL-7/15 (10ng/ml each) 
then expanded in either IL-2 (40U/ml) or IL-7/15 (10ng/ml each).  Samples were taken on 
days (A) 0, (B) 1, (C) 3, and (D) 7 of expansion and stimulated with media alone (NIL), 
with irradiated splenocytes (IRR SPLEEN), or irradiated splenocytes pulsed with the 
specific peptide, gp100 (GP100). Cells were incubated with stimulants with a ratio of 10:1 
in 24 well plates at a concentration of 2x106/ml. Supernatant was collected 24hrs after 
exposure to stimulants and assayed for IFN-γ using the murine IFN-γ ELISA kit.  Data is 
shown as the mean of duplicates ± SD. 
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Adoptive Transfer of IL-7/15 Expanded B/I Activated DLN Cells Eliminates Melanoma 
Lung Metastases 
 Lymphocytes grown in IL-7/15 showed a potent IFN-γ response to specific peptide 
ex vivo.  Therefore, we hypothesized that this activity would extend in vivo and mediate 
tumor regression.  In an adoptive immunotherapy experiment, C57Bl/6 mice inoculated 
with B16F10 melanoma cells intravenously were treated with B/I activated DLN cells 
expanded in different cytokines.  Mice were given different doses of DLN cells to 
determine the optimal T cell dose needed to cure B16F10 pulmonary metastases generated 
by an initial tumor cell dose of 250,000 cells per mouse.  Summary statistics are shown in 
Table 2.  All treated groups were significantly different from the untreated control group 
(CON), p-value < 0.003 (Fig. 5).  Groups treated with AIT at T cell doses of 7.5x106 and 
15x106 were significantly different from CYP only group (p-value < 0.004).  
Cyclophosphamide is an alkylating agent that may have direct antitumor effect and causes 
lymphodepletion in mice, eliminating cytokine sinks and regulatory T cells that compete 
with and inhibit the adoptively transferred T cells.  Thus, mice treated with AIT are 
generally given cyclophosphamide in our lab.  When given as a single drug agent, 
cyclophosphamide slowed tumor progression (Fig. 5, CYP).  Both IL-2 and IL-7/15 
expanded DLN cells were ineffective at a dose of 2x106/mouse, compared to CYP alone.  
IL-2 and IL-7/15 expanded cells were equally potent against the melanoma cells at a dose 
of 7.5 x106.  Complete tumor regression was observed in most mice when DLN cells were 
given at 15x106 cells per mouse.  At this concentration, IL-7/15 expanded DLN cells were 
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significantly more effective than IL-2 expanded cells, causing complete tumor regression 
in all mice while IL-2 only caused complete remission in one out of six mice.  Thus, IL-
7/15 expanded B/I activated DLN cells were as potent if not more potent against B16F10 
melanoma as IL-2 expanded cells.    
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Figure 5: IL-7/15 expanded DLN cells were as effective as IL-2 expanded cells at 
curing B16F10 Lung Metastasis.  
 
Recipient C57BL/6 mice were injected intravenously with 250,000 B16F10 melanoma 
cells and randomized to 8 treatment groups: untreated control (CON), cyclophosphamide 
(CYP) treated (100mg/kg), and CYP + AIT with IL-2 or IL-7/15 expanded DLN cells at 
doses of 2, 7.5, and 15x106 cells/mouse (doses shown in parenthesis). CYP was given 3 
days after tumor inoculation and AIT was performed the following day.  After 24 days, 
lungs were harvested and lung metastasis were counted.  The data shown is the mean 
number of lung metastasis ± SE of 6 mice per group. All treated groups were significantly 
different from CON and groups treated with AIT at T cell doses of 7.5x106 and 15x106 
were significantly different from CYP only group (Wilcoxon rank sum test, p-value < 
0.05). (A) AIT Schemata (B) Results 
 
 
  
 
 
Table 2: Summary Statistics of Figure 5B. 
GROUPS   N Mean SE Lower 
95% 
Upper 95% 
CON   6 250.0 0.00 250.0 250.0 
CYP   6 139.3 22.94 80.36 198.3 
IL-2 (2)   6 136.7 27.27 66.55 206.8 
IL-2 (7.5)   6 13.83 4.915 1.198 26.47 
IL-2 (15)   6 1.33 0.422 0.249 2.417 
IL-7/15 (2)   6 102.7 13.88 66.98 138.4 
IL-7/15 (7.5)   6 5.00 1.897 0.123 9.877 
IL-7/15 (15)   6 0.00 0.00 0.00 0.00 
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Conclusions 
 
 Our preliminary data showed that IL-7 and IL-15 supported expansion of B/I 
activated DLN cells 2-3 and 5-fold greater than IL-2.  When we combined IL-7 and IL-15, 
there was an additive effect so that IL-7/15 expanded DLN cells 8.6-fold greater than IL-2 
(Fig. 2).  As we’ve discovered, this difference in proliferation was partly attributed to the 
pro-survival role of these alternate cytokines.  IL-7/15 expanded B/I activated DLN cells 
have a smaller proportion of apoptotic cells than IL-2 expanded cultures (Fig. 3).  This 
protection from apoptosis also allowed IL-7/15 expanded cells to expand for a longer 
period than IL-2 expanded cells.  B/I activation and expansion with IL-2 and IL-7/15 
enriched for T cells resulting in a population composed almost entirely of CD4+ and CD8+ 
T cells (Table 1).  During the growth phase of expansion, IL-7/15 induced similar T cell 
subsets as IL-2, but maintained central memory CD8+ T cells better than the prototypical 
cytokine on Day 7 (Table 1).  IL-7/15 expanded DLN cells showed an increase in IFN-γ 
secretion in response to specific antigen while IL-2 expanded DLN cells declined in 
reactivity over the course of ex vivo culture (Fig. 4).  This response to tumor antigen by IL-
7/15 expanded cells extended in vivo, causing 100% regression of pulmonary metastases at 
a dose of 15x106 cells per mouse, which is significantly better than the 17% cure rate 
achieved with IL-2 expanded cells (Fig. 5, Table 2).   
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{Chapter 4: Treating Tumor Bearing Mice with Gemcitabine 
Eliminates Myeloid Derived Suppressor Cells and Improves 
Expansion of T cells } 
 
Introduction 
Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of 
immature monocytes and granulocytes that cause T cell dysfunction in tumor bearing mice 
and humans68-73, 75.   These CD11b+/Gr-1+ cells accumulate in the bone marrow, blood, 
spleen, lymph nodes, and at the tumor site in tumor bearing hosts.  Accumulation of 
MDSCs is caused by the tumor microenvironment through secreted factors that stimulate 
myelopoiesis and maintain the immature state of myeloid cells70.   
MDSCs present a barrier to successful AIT and therefore, are potential targets for 
augmenting treatment of cancer.  Several methods have been developed to deplete MDSCs 
directly, to decrease MDSC numbers indirectly by stimulating differentiation into 
nonsuppressive mature immune cells, and to inhibit products secreted by MDSCs 71, 79, 80, 
83.  One of the most promising of these methods is administration of 2’,2’-
difluorodeoxycytidine or gemcitabine (GEM).  GEM is a cytidine analogue that has been 
used as an antimetabolite against non-small-cell lung cancer, ovarian cancer, and breast 
cancer86.    GEM works during the S phase of the cell cycle, acting as a competitive 
inhibitor of DNA polymerase and incorporating into DNA.  In addition, the drug inhibits 
ribonucleotide reductase and thereby reduces the pools of deoxyribonucleotides available 
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for DNA synthesis.  GEM is believed to be tumoricidal, inducing apoptosis caused by 
early termination of DNA synthesis.  In mice, GEM has a plasma half life of 0.28 hr after a 
dose of 20mg/kg given intravenously and 86.3% is excreted in urine 24 hrs after 
administration 92.  The drug is quickly distributed in the spleen, thymus, testicles, kidney, 
femur, small intestines, and lymph nodes.   
Although GEM has been associated with myelosuppression, it has not been applied 
clinically as an agent to abrogate the immunosuppression caused by MDSCs.  The purpose 
of the following studies is to elucidate the mechanism by which GEM exerts its inhibitory 
effects.  Our goal is to determine whether the observed suppression of MDSCs is a direct 
effect of the drug or an indirect result of cytotoxicity to tumor cells.  Doing so will help 
clarify whether gemcitabine is a good treatment option for abrogating the 
immunosuppression caused by MDSCs. 
 
Materials and Methods 
Mice     
Virus-free BALB/c and athymic nude mice (National Cancer Institute) were used 
between 8 and 12 weeks of age.  Animals were caged in groups of 6 or fewer and provided 
food and water ad libitum. All guidelines of the Virginia Commonwealth University 
Institutional Animal Care and Use Committee, which conform to the American 
Association for Accreditation of Laboratory Animal Care and the U.S. Department of 
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Agriculture recommendations for the care and humane experimental use of animals, were 
followed.  
Tumor Cell Lines 
4T1 mammary tumor cells were kindly provided by Dr. Jane Tsai at the Michigan 
Cancer Foundation, Detroit, Michigan. Cells were passaged in complete Dulbecco’s 
Modified Essential Medium (DMEM) with 10% heat-inactivated fetal calf serum 
(Hyclone, Logan, UT), 1mM sodium pyruvate (Mediatech, Inc, Herndon, VA) , 100 U/ml 
penicillin (Invitrogen, Grand Island, NY), 100 ug/ml streptomycin, 0.075% sodium 
bicarbonate, and 10mM HEPES buffer.  Meth A sarcoma, an unrelated tumor cell line 
(ATCC, Rockville, MD) was maintained in complete RPMI 1640 with 10% heat-
inactivated fetal calf serum, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 
0.075% sodium bicarbonate, 2mM L-glutamine, 100 U/ml penicillin, 100 μg/ml 
streptomycin, 10 mM Hepes buffer, and 5×10-5M 2-mercaptoethanol (Sigma, St. Louis, 
MO).  All cells were incubated in 250 ml T-flasks (PGC, Gaithersburg, MD) at 37oC in 
humidified air with 5% CO2.  Tumor cells were harvested for inoculation of mice with 
0.05% trypsin-EDTA (Invitrogen), washed twice with 1xPBS and resuspended in 1xPBS.   
Tumor Inoculation  
BALB/c and nude mice were inoculated subcutaneously (S.C.) in the flank with 
50,000 4T1 mammary carcinoma cells.  Tumor growth was monitored with bidirectional 
tumor measurements every 2-3 days.  The product of the two perpendicular measurements 
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measured with a caliper was recorded as the tumor area in mm2.  Results are reported as 
the mean tumor area ± standard error (SE) with 3-6 mice per group.  
 
Cyclophosphamide and Gemcitabine Treatments 
Cyclophosphamide (CYP) was given at a dose of 100mg/kg via intraperitoneal 
(I.P.) injection on day 5 after tumor inoculation (Bristol-Myers Squibb Company, 
Princeton, NJ).  Gemcitabine-HC1 (GEM) was given at 60mg/kg via I.P. injection (Eli 
Lilly and Company, Indianapolis, IN).  Two GEM treatment regimens were employed: 1) 
EARLY GEM: GEM was given on day 5 after 4T1 tumor inoculation and repeated once 
weekly 2) LATE GEM: was given in a single dose on day 20-25.   
  
Spleen Harvest and Expansion of Splenocytes  
Spleens were harvested 24-48hr after GEM treatment in complete RPMI, weighed, and 
crushed through a cell strainer.  Splenocytes were resuspended in 1x ammonium chloride 
solution to lyse red blood cells.  Splenocytes were stained with 0.04% tryphan blue to 
exclude dead cells and numbers were counted under a light microscope using a Neubauer 
type hemacytometer.  Splenocytes that were expanded were first subjected to Ficoll density 
gradient centrifugation to isolate splenic lymphocytes. Splenic lymphocytes were brought 
to a concentration of 1x106 cells/ml and activated by incubation with 5 nM bryostatin-1 
(provided by the National Cancer Institute, Bethesda, MD), 1 uM ionomycin (Calbiochem, 
San Diego, CA) (B/I), and 80U/ml of rIL-2 (Chiron, Emeryville, CA) in 50ml conical 
polystyrene tubes at 37°C, 5% CO2, for 18 hours.  Cells were washed three times with 
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warm complete RPMI and resuspended at 1x106 cells/ml.  Splenocytes were expanded in 
complete RPMI supplemented with an additional 5% heat-inactivated fetal calf serum with 
either 40U/ml of rIL-2 or an alternating regimen whereby B/I activated splenocytes were 
incubated for 24hrs in IL-7/15 (10ng/ml each, Peprotech Inc, Rocky Hill, NJ) then exposed 
to IL-2 for 24hrs and recultured in IL-7/15 for the remainder of the expansion period.  The 
cells were allowed to proliferate in culture until peak growth was reached and were split 
every 2-3 days in order to maintain 1x106 cells/ml concentration. 
 
Bone Marrow Harvest and Collection of Peripheral Blood 
 Tibia and femur from euthanized mice were collected and flushed with complete 
RPMI to collect bone marrow.  Red blood cells were lysed with a 1x ammonium chloride 
solution, washed twice with 1xPBS, brought to 1x106/100uL and stained for MDSCs.  
Blood from the hearts of euthanized mice was collected into an anti-clotting solution (5uM 
EDTA in PBS), washed with FACS Buffer (2% FBS + 0.1% sodium azide in PBS), 
resuspended in 100uLs FACS buffer and stained for MDSCs.  After staining, red blood 
cells were lysed with 1x ammonium chloride solution.  Cells were fixed in 2% 
paraformaldehyde for later analysis.     
 
Staining for Myeloid Derived Suppressor Cells 
Cells were brought to 1x106 in 100ul and stained for 30 minutes with anti-mouse 
CD11b and anti-mouse Ly-6G/Ly-6C(Gr-1) (Biolegend, San Diego, CA).  Unstained cells 
were used as a negative control and rat IgG2b,κ was used as the isotype control. Staining 
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with Cd11b alone or Gr-1 alone were used as single color positive controls.  Stained cells 
were fixed with 2% paraformaldehyde and analyzed within 7 days of staining on an ELITE 
Beckman Coulter flow cytometer. 25,000 cells per sample were analyzed. 
  
Interferon-γ Release Assay  
Interferon γ (IFN-γ) release from tumor sensitized, B/I activated and expanded 
splenic lymphocytes in response to various stimulants was assayed using ELISA. The 
splenic lymphocytes were cultured in 24-well plates at 2x106 cells/ml with either no 
stimulants, irradiated (10,000 rads) 4T1 mammary carcinoma cells, or irradiated MethA 
sarcoma (negative control).  Lymphocyte to stimulator ratio was 10:1. After 24 hours of 
culture, supernatants were harvested and stored at -20°C until assayed using a murine IFN-
γ ELISA kit (BD Biosciences Pharmingen, San Diego, CA). Results reported are the mean 
values of duplicate ELISA wells ± SD. 
   
In vitro Assay of Gemcitabine Effect on 4T1 Mammary Carcinoma Cells  
Two methods were used:  1) 4T1 mammary cells were cultured in 24 well plates as 
duplicates at a concentration of 200,000 cells/ml in media, 60ng/ml  GEM, 300ng/ml 
GEM, or 1500 ng/ml GEM.  Cells were stained 0.04% tryphan blue and counted at 0hr, 
24hr and 48hr using a light microscope and a Neubauer type hemacytometer. Data shown 
are means of duplicate wells ± SEM. 2) MTT assay: 4T1 mammary carcinoma cells were 
treated with 0, 3.6ng/ml, 32.4ng/ml, or 97.2ng/ml GEM and incubated in 96 well plates for 
48hrs and 72hrs at 2,000, 5,000, 10,000, and 20,000 cells per well.  After incubation, 10ul 
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of MTT yellow tetrazolium salt was added and standard MTT assay protocol was 
followed, with absorption at 550nm  (MTT Proliferation Kit I, Roche Applied Science, 
Indianapolis, IN).  Data generated are means of duplicate wells ± SE. 
Adoptive Immunotherapy Using GEM to Treat Recipients 
Recipient BALB/c mice were inoculated with 50,000 4T1 cells in the flank and 
randomly divided into four treatment groups with 6 mice per group: untreated controls 
(CON), GEM treated (GEM ONLY), AIT treated (AIT ONLY), and GEM combined with 
AIT (GEM + AIT). GEM treatment was given on days 6 and 11 at a dose of 60mg/kg. AIT 
was given on day 7 via I.V. using 4T1 sensitized DLN cells at a dose of 50x106 cells per 
mouse.     
Adoptive Immunotherapy Using GEM to Treat Donors 
BALB/c mice were injected in the flank with 50,000 4T1 cells.  Mice were either 
treated with GEM (60mg/kg) or untreated on Day 20 and spleens were harvested 48hrs 
later.  Mononuclear lymphocytes were isolated via ficoll density gradient centrifugation. 
Splenic lymphocytes were activated and expanded as above.  Recipient BALB/c mice were 
inoculated in the flank with 10,000 4T1 cells.  Three days later, mice were randomly 
divided into treatment groups with 6 mice per group: untreated controls (CON), CYP 
ONLY, CYP + AIT with untreated donor lymphocytes (CYP + AIT CON), and CYP + 
AIT with GEM treated donor lymphocytes (CYP + AIT GEM). CYP (100mg/kg) was 
given three days after tumor inoculation and AIT was given 24hrs after CYP treatment at a 
dose of 18x106 T cells/mouse. 
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 Statistics 
Differences between two groups were analyzed with the student’s t-test. 
Differences among more than two groups were assessed by analysis of variance (ANOVA) 
and Tukey-Kramer honestly significant difference test (Tukey’s HSD) using JMPIN 
software (SAS Institute Inc., Cary, N.C.). Results of tumor growth are presented as the 
means ± standard errors (SE) of tumor area in each treatment group. Tumor growth 
experiments were repeated at least 2 times.  In vivo experiments included three to six mice 
per group.  In vitro assays were repeated at least twice. An α < 0.05 was used throughout to 
determine significant differences. 
 
Results 
Early Gemcitabine Treatment inhibits 4T1 flank tumor growth in BALB/c Mice, reverses 
splenomegaly, and suppresses MDSC accumulation in the spleen.   
 Sinha et al. reported that gemcitabine (GEM) treatment given one day after 
injection of 7000 4T1 cells into BALB/c mice resulted in delayed primary tumor growth 
and lower MDSC numbers in the blood of tumor bearing mice77.  They argued that the 
decrease in MDSCs is a direct effect of GEM treatment, which then slowed tumor growth.  
Tumor cells secrete factors that recruit and induce the accumulation of MDSCs.  
Therefore, we questioned the validity of the conclusion drawn by Sinha et al. because 
GEM may directly inhibit tumor growth and thereby, indirectly inhibit MDSC 
accumulation as a secondary effect.  With a small tumor dose and treatment 24hr after 
injection, the tumor cells have not had the time to adjust to the host environment and may, 
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therefore, be highly susceptible to GEM toxicity.  We wanted to repeat the experiment to 
verify that the effects of GEM on tumor growth is measurable even after the tumor has 
been established, typically 5 days after injection, and at a higher dose of tumor inoculum.  
If GEM has no effect on established tumor growth, then its inhibitory influence on MDSCs 
must be direct.  In addition, we wanted to investigate the combined effect of GEM and 
cyclophosphamide (CYP), a lymphodepleting drug used in our adoptive immunotherapy 
protocols.  Therefore, BALB/c mice were injected subcutaneously with 50,000 4T1 cells in 
the flank and either treated with GEM (60mg/kg) on day 5, with CYP (single dose, 
100mg/kg), with CYP and GEM, or left untreated.  GEM was given once a week after the 
first dose and spleens were harvested at various times for analysis.   
Like Sinha et al., we observed delayed tumor progression in GEM treated animals, 
even at a higher dose of tumor inoculation and at a later time of GEM treatment.  After 21 
days of tumor growth, untreated controls had tumors that were 72.4±8.06mm2 compared to 
29.8±4.2 for the GEM treated group and 23.0±1.7 for CYP + GEM group (Fig. 6A).  The 
difference in tumor area between the untreated group and groups treated with GEM was 
significant (p-value < 0.05).  In tumor bearing mice, splenomegaly was observed with 
increasing tumor burden (Fig. 6B+C).  In naive mice, spleen weight averaged 
138.5±4.65mg with an absolute splenocyte count of 103.79±7.14 x106 and 2.81±0.28% 
MDSCs (average of 13 mice).  In untreated tumor bearing mice, an increase of 200-300% 
can be observed in spleen weight and an increase of 300-700% in splenocyte numbers, 
depending on the size of the tumor.  Accumulation of MDSCs was observed with 
increasing tumor burden so that by day 18, MDSCs made up 30% of the spleen cells in 
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untreated controls (Fig. 6D).  The two groups treated with GEM showed a drop to 10% and 
13% MDSCs in the spleen.  The difference in MDSCs between control and GEM treated 
groups is even more dramatic for the absolute number of MDSCs (Fig. 6E).  The combined 
treatment with GEM and CYP did not have an additive or synergistic effect on tumor 
progression.  CYP alone had only a weak effect on tumor growth, and did not inhibit 
MDSCs and when combined with GEM, the results on tumor growth and MDSCs mirrored 
those of the GEM group.    
 Because gemcitabine inhibited both tumor growth and accumulation of MDSCs, it 
is difficult to make conclusions about the pharmacologic mechanism.  If this drug is to be 
used to combat MDSCs then it is important to confirm that it in fact acts on these cells.  
We were left questioning whether or not the reduction of MDSC accumulation in tumor 
bearing BALB/c mice is caused by a direct effect of gemcitabine on MDSCs or by an 
indirect cytotoxic effect of the drug on 4T1 mammary carcinoma cells or both.    
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6C. Days post Tumor Inoculation
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6E. Days post Tumor Inoculation
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Figure 6: Early gemcitabine treatment of BALB/c mice bearing established 4T1 flank 
tumors delays tumor growth, reverses splenomegaly, and inhibits MDSC 
accumulation in the spleen.  
BALB/c mice were injected with 50,000 4T1 cells in the flank and were randomly 
assigned to one of five treatment groups: untreated controls (CON), cyclophosphamide 
(CYP) treated (2mg/dose), gemcitabine (GEM) treated (60mg/kg), and CYP+GEM. GEM 
treatments were given on days 5, 15, and 21.  Spleens from representative animals were 
harvested on days 4, 7, 11, and 18.  The spleens were weighed and stained for MDSCs 
using anti-CD11b antibody (FITC) and anti-GR-1 antibody (PE). Gemcitabine’s effect on 
(A) tumor growth represented by area in mm2±SE (5 mice per group), (B) spleen weight on 
day 18, (C) absolute number of splenocytes, (D) percentage MDSCs in the spleen, and (E) 
absolute number of MDSCs are shown.  Statistical analysis was performed on tumor areas 
measured on Day 18. The groups’ mean tumor area were compared using ANOVA and 
found to be significantly different (F(3,16) = 9.5, p-value = 0.0008).  Using Tukey’s HSD, 
it was determined that the untreated control had significantly larger tumor than the GEM 
and GEM+CYP treated groups (p < 0.05). Within the three treated groups: CYP, GEM, 
CYP + GEM, there was no significant difference.  Differences shown between control and 
GEM treated groups are typical of three independent experiments.          
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Gemcitabine Directly Inhibits 4T1 Mammary Carcinoma Cell Growth 
 
 To begin answering the question we posed, we tested the direct effects of 
gemcitabine on 4T1 mammary carcinoma cells in vitro.  Duplicate wells of 4T1 cells were 
incubated for 24 and 48hr with a physiologically relevant concentration of GEM 
(300ng/ml) and doses 5-fold lower and higher.  Viable cell numbers were counted via 
trypan blue exclusion (Fig. 7A).  Untreated controls showed a 3-fold increase in numbers 
after 24 hours and after reaching confluence, cell numbers declined sharply.  GEM treated 
groups showed a dose dependent inhibition of cell growth.  Table 3 represents data from an 
MTT assay that verifies the results shown in figure 7.  Again, untreated cells showed an 
increase in cell number over time, which is indicated by an increase in the optical density.  
GEM treated groups showed a dose dependent inhibition of proliferation for all starting 
concentrations of 4T1 cells.  A concentration as little as 3.6ng/ml of GEM is enough to 
effectively prevent progression through the cell cycle.  Because GEM is an antimetabolite, 
its inhibitory effect on cell division is expected, especially on rapidly dividing cancer cells.  
The results of these in vitro assays suggest that GEM acts directly on 4T1 cells and this 
inhibition on tumor growth may contribute to the decrease in MDSCs observed in treated 
mice. 
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Figure 7: Gemcitabine Has a Direct Effect on 4T1 Mammary Carcinoma Cell 
Growth 
4T1 mammary carcinoma cells were cultured in 24 well plates in duplicates at a 
concentration of 200,000 cells/ml in media, 60ng/ml  GEM, 300ng/ml GEM, or 1500 
ng/ml GEM.  Cells were counted at 0hr, 24hr and 48hr and data shown is mean cell 
number ± SE. Differences are typical of two independent experiments. 
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Table 3: MTT Assay of Gemcitabine Effect on 4T1 Mammary Carcinoma Cell Proliferation. 
4T1 cells treated with 0, 3.6ng/ml, 32.4ng/ml, or 97.2ng/ml of GEM and incubated in 96 well plates for 48hrs at 2,000, 5,000, 
10,000, and 20,000 cells per well.  After incubation, 10ul of MTT yellow tetrazolium salt was added and standard MTT assay 
protocol was followed.  Data shown is mean optical density±SE of duplicates. 
 
 
  
2,000 4T1 Cells 5,000 4T1 Cells 10,000 4T1 Cells 20,000 4T1 Cells 
GEM 
 
48 hrs 72 hrs 48 hrs 72 hrs 48 hrs 72 hrs 48 hrs 72 hrs 
0 ng/ml 
 
0.436±0.0130 0.914±0.0300 0.593±0.0500 1.201±0.0130 0.828±0.0540 1.488±0.0800 0.971±0.0600 1.567±0.0175 
3.6 ng/ml 
 
0.338±0.0075 0.278±0.0705 0.461±0.0060 0.517±0.0365 0.616±0.0095 0.629±0.0250 0.721±0.0300 0.735±0.0790 
32.4 ng/ml 
 
0.177±0.0160 0.124±0.0040 0.247±0.0070 0.161±0.0040 0.334±0.0225 0.210±0.0050 0.507±0.0125 0.324±0.0010 
97.2 ng/ml 
 
0.166±0.0015 0.116±0.0050 0.217±0.0025 0.163±0.0120 0.306±0.0190 0.172±0.0125 0.487±0.0300 0.296±0.0260 
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The Inhibitory Activity of Gemcitabine on 4T1 Growth, Splenomegaly, and MDSC 
Accumulation in the Spleen of BALB/c Mice is Mediated by the Drug’s Direct Effect on 
MDSCs.  
 Although GEM has a direct effect on 4T1 mammary carcinoma cells, it is possible 
that the chemotherapy drug also directly inhibits MDSCs.  We hypothesized that if 
MDSCs were directly inhibited by GEM then immunosuppression of T cells would be 
lifted and the delayed tumor growth might result from an antitumor immune response.  
Therefore, we tested the effects of GEM on tumor growth in nude mice. Nude mice were 
inoculated with 50,000 4T1 cells and were either untreated or treated with GEM once a 
week starting on day 5.  Untreated BALB/c mice injected with the same tumor inoculum 
were used for comparison of tumor kinetics.  While there were no significant differences in 
tumor kinetics between BALB/c mice and nude mice, tumor growth was significantly 
delayed in nude mice that were treated with GEM (Fig. 8, Tukey’s HSD, p-value<0.05).  
We superimposed the tumor growth curves in this experiment with a prior experiment 
performed in BALB/c mice following the same protocol.  The tumor growth curves in 
BALB/c mice were the same in both experiments, allowing us to compare the extent of 
growth inhibition by GEM in nude mice versus BALB/c mice.  GEM had similar potency 
against tumor growth in both nude and BALB/c mice, inhibiting growth by 2-fold and 2.6-
fold, respectively.  Thus, it appears as though the inhibitory effect of GEM on tumor 
progression when administered at Day 5 and then weekly is independent of T cells.   
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Figure 8: Gemcitabine inhibits 4T1 flank tumor growth in nude mice. Nude mice were 
injected with 50,000 4T1 cells in the flank and were randomly assigned to one of two 
treatment groups: untreated controls (CON) and gemcitabine (GEM) treated (160mg/kg). 
GEM treatments were given on days 5, 12, and 17.  BALB/c mice given the same tumor 
inoculation without GEM treatment were used for comparison of tumor growth.  (A)  
Gemcitabine’s effect on tumor growth represented by area in mm2±SE (6 mice/group).  (B) 
Data from the same experiment performed in BALB/c mice (PRIOR BALB/C) were 
superimposed on data from nude mice experiment for comparison.  Statistical analysis was 
performed on tumor areas measured on Day 19.   ANOVA: F(2,15) = 13.8, p-value = 
0.0004. 
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To continue investigating whether or not GEM directly inhibits MDSCs, we 
allowed 4T1 flank tumors to grow to a large size, ≥60mm2, before treating with a single 
dose of GEM (60mg/kg).  Spleens were harvested 24 hr or 48 hr after treatment.  We 
hypothesized that within this short period of time tumor size would not change 
significantly.  Therefore, if gemcitabine administered only once at 3 weeks of tumor 
growth decreased MDSC proportion in the spleen, it is likely to be through a direct effect 
on these cells and not an indirect effect caused by inhibition of tumor growth.  GEM 
treatment for as little as 24hr was enough to reverse the splenomegaly observed in 
untreated controls and decreased the proportion and absolute number of MDSCs by 172% 
and 664%, respectively (Fig. 9).  This inhibition on MDSCs occurred even though there 
was no significant difference in tumor size between untreated and treated groups 24 hr and 
48hr after treatment (Fig. 9 + 10).   
In addition to the spleen, MDSCs accumulate in the bone marrow and peripheral 
blood of tumor bearing mice.  We examined at the bone marrow and peripheral blood to 
determine whether or not the influence of GEM on MDSCs is widespread.  In the bone 
marrow and peripheral blood, MDSCs make up 32.6±2.19% and 23.2±3.79%, respectively 
(Fig. 10).  MDSCs accumulate in the bone marrow to 78.8±3.29% and peripheral blood to 
76.4±2.03% in tumor bearing mice, an increase of greater than 100%.  Although less 
effective in the bone marrow, GEM decreased MDSC development here as well as the 
peripheral blood.   
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9E.  
Figure 9: Late Treatment of Gemcitabine Reverses Splenomegaly and Suppresses 
MDSC Accumulation in the Spleen, Despite No Effect on Tumor Size.  
BALB/c mice were injected with 50,000 4T1 cells in the flank and were randomly 
assigned to one of three treatment groups: untreated controls (CON), GEM treatment for 
24hrs(GEM 24hr, 60mg/kg), and GEM treatment for 48hr (GEM 48hr). 3 tumor-free mice 
were used as naive controls (NAIVE). GEM was given once on day 20 to the 48hr group 
and on Day 21 to the 24hr group. Spleens were harvested on day 22. Tumor size was 
measured on days 20, 21, and day 22. The spleens were weighed and stained for MDSCs 
using anti-CD11b antibody (PE, 5uL) and anti-GR-1 antibody (FITC, 1.25uL). 
Gemcitabine’s effect on (A) tumor growth, (B) spleen weight, (C) absolute number of 
splenocytes, (D) percentage MDSCs in the spleen, and (E) absolute number of MDSCs 
calculated as the product of C and D are shown.  Statistical analysis was performed on day 
22 measurements. Data are shown as mean±SE (3 mice/group). Differences between 
untreated control and mice treated with late GEM regimen are representative of three 
independent experiments.  (A) F (2, 3.6) = 0.74, p-value = 0.5327, (B) F(3,3.7) = 11.0, p-
value = 0.0258, (C) F(3,4.0) = 25.4, p-value = 0.0048, (D) F(3,8) = 28.3, p-value = 0.0001.  
(B-D) Mean values of NAIVE, GEM 24hr, and GEM 48hr were significantly different 
from CON as determined by Tukey-Kramer HSD. Asterisks of different colors represent 
significant differences between the means as determined by Tukey-Kramer HSD (p-value 
< 0.05). 
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Figure 10:  Late Treatment of Gemcitabine inhibits MDSC accumulation in the 
spleen, bone marrow, and blood.   
BALB/c mice were inoculated in the flank with 4T1 mammary carcinoma cells. 20 days 
later, mice were randomly assigned to untreated control group (CON) or GEM treated 
group (GEM).  GEM was given I.P. at 60mg/kg.  Three mice were used as tumor free 
controls (NAIVE).  Spleens, bone marrow and blood was harvested 48hrs after GEM 
treatment.  GEM effect on (A) tumor area, (B) spleen weight, (C) splenocyte number, and 
(D) MDSC proportion in spleen, bone marrow, and blood.  (A+B) Mean±SE (6 
mice/group). (C+D) Mean±SE (3 mice/group).  (A) two-tailed student’s t-test. Day 20: t = 
1.16, df = 6.41. p-value = 0.2890, Day 22: t=1.43, df = 7.02, p-value = 0.1950 (B) 
ANOVA: F(2,12) = 54.0, p-value < 0.0001 (C) ANOVA: F(2,6) = 54.2, p-value = 0.0001 
 (D) spleen: F(2, 3.4) = 293.5, p-value = 0.0002, bone marrow: F(2,3.5) = 29.1, p-value = 
0.0008, blood: F(2, 3.4) = 70.0, p-value = 0.0018. Asterisks indicate significant 
differences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
Gemcitabine Treatment of Tumor Bearing Mice Helps Restore CD8+ T cell Immune 
Function 
 MDSCs inhibit T cells through  various direct and indirect mechanisms 70, 72-76, 79-81.  
If GEM inhibits MDSCs, then immunosuppression of T cells should be abrogated by 
GEM.  We decided to investigate MDSC suppression of activated T cell proliferation and 
response to tumor antigen.  Splenocytes harvested from untreated and GEM treated mice 
bearing large tumors were enriched for mononuclear lymphocytes through ficoll density 
gradient centrifugation.  Splenic lymphocytes were cultured for 24hrs with media, 
irradiated 4T1 mammary carcinoma cells, or irradiated Meth-A sarcoma cells.  Meth-A 
sarcoma cells were used as a negative control for these 4T1 primed T cells, which should 
respond to 4T1 cells and secrete interferon- γ (IFN-γ).  Naive splenic lymphocytes were 
also used as a negative control.  These unsensitized T cells should have little to no 
specificity for 4T1 cells.  Splenic T cells from untreated, tumor bearing mice had 
dampened responses to antigen stimulation so that IFN-γ concentrations were as low as 
those of unsensitized, naive T cells (Fig. 11A).  This tolerance was lifted when GEM was 
given to tumor bearing mice.   
Splenic lymphocytes from mice in this experiment were also activated with 
bryostatin-1/ionomycin plus IL-2, and expanded with an alternating regimen of IL-7/15 
and IL-2 cytokines.  Our preliminary data showed that this alternating regimen resulted in 
the greatest expansion of T cells.  Even at its peak of growth, on day 13, splenic 
lymphocytes from untreated tumor bearing mice had 150% less expansion than 
lymphocytes from mice treated with GEM 24hrs before harvest and 300% less than 
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lymphocytes from mice treated with GEM 48hrs before harvest (Fig. 11B).  After 16 days 
of expansion the difference in growth of T cells from mice that were untreated and those 
treated for 48hr with GEM reached >500%.  To confirm this difference, splenic 
lymphocytes from the CON and GEM 48hr groups were expanded in IL-2 or IL-7/15 (Fig. 
11C+D).  A similar difference in proliferation was observed between the two groups.   In 
addition, after 11 days of expansion away from the immunosuppressive influence of 
MDSCs, T cells from untreated tumor bearing mice were rescued from tolerance, secreting 
IFN-γ in response to 4T1 cells, but still at lower levels comparable than T cells from mice 
treated with GEM for 24hrs (Fig. 11E).            
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Figure 11: Gemcitabine treatment augments splenic T cell expansion in vitro and 
restores T cell ability to respond to antigenic stimulus.  
BALB/c mice were injected with 50,000 4T1 cells in the flank and were randomly 
assigned to one of three treatment groups: untreated controls (CON), GEM treatment for 
24hrs (GEM 24hr, 60mg/kg), and GEM treatment for 48hr (GEM 48hr).  GEM was given 
once on day 20 for the 48hr group and on Day 21 for the 24hr group.  Spleens were 
harvested on day 22. Three tumor-free mice were used as naive controls (NAIVE).  
Splenocytes were enriched for lymphocytes by ficoll density gradient centrifugation or by 
passage through a nylon wool column. (A) Splenic lymphocytes were incubated with 
(irradiated 4T1 cells or irradiated MethA cells) or without stimulus for 24 hours and IFN-γ 
secretion was measured pre-expansion. (B) Splenic lymphocytes were pulsed for 18hr in 
B(5nM)/I(1uM) + IL-2 (80U/ml) then expanded using the alternate cytokine regimen, 
where cells were expanded on day 1 in IL-7/15 (10ng/ml) then exposed to IL-2 (40U/ml) 
on day 2, and placed back in IL-7/15 on day 3. Differences between untreated and treated 
mice are typical of two independent experiments. (C) Splenic lymphocytes from CON and 
GEM 48hr group expanded in IL-2 (40U/ml). (D) Splenic lymphocytes from CON and 
GEM 48hr group expanded in IL-7/15 (E) Splenic lymphocytes were incubated with 
(irradiated 4T1 cells or irradiated MethA cells) or without stimulus for 24 hours and IFN-γ 
secretion was measured on day 11 of expansion. Data is shown as mean ± SD (A+E).  
Results typical of two independent experiments.  
 
107 
 
Successful Adoptive Immunotherapy Partly Depends on Administration of a Large Dose of 
Tumor Specific T cells  
 
 We have shown that splenic T cells from tumor bearing mice that have been treated 
with GEM expand to a greater extent in response to mitogenic cytokines than untreated 
tumor bearing mice and demonstrate greater antitumor function in vitro.  We next 
questioned whether or not this GEM rescued T cell function can inhibit tumor progression 
in vivo.  Thus, an AIT experiment was performed using GEM treated and untreated 
BALB/c mice bearing large 4T1 tumors as donors (Fig. 12).  Tumor growth in mice treated 
with AIT + CYP showed similar kinetics as tumor growth in mice treated with CYP alone 
(p>0.05).  Thus, AIT with 18x106 T cells harvested from GEM treated and untreated 
BALB/c mice bearing 22 day old tumors was ineffective.  The results of this experiment 
suggest that with all other variables remaining constant, a larger dose of T cells may be 
necessary to exert a significant inhibition on tumor progression.  This will have to be tried 
in future experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
Days post Tumor Inoculation
0 5 10 15 20 25 30 35
T
u
m
o
r 
A
re
a
 (
m
m
2
)
0
20
40
60
80
100
CON 
CYP 
CYP + AIT CON 
CYP + AIT GEM
 
 
 
Figure 12: AIT with T cells from mice with 22 day old 4T1 tumors at a dose of 18x106 
T cells does not inhibit 4 day old 4T1 tumors.  
BALB/c mice were injected in the flank with 50,000 4T1 cells. Mice were either treated 
with GEM (60mg/kg) or untreated on Day 20 and spleens were harvested 48hrs later.  
Mononuclear lymphocytes were isolated via ficoll density gradient centrifugation. Splenic 
lymphocytes were activated and expanded as in Fig. 11B.  Recipient BALB/c mice were 
inoculated in the flank with 10,000 4T1 cells.  Three days later, mice were randomly 
divided into treatment groups: untreated controls (CON), CYP ONLY, CYP + AIT with 
untreated donor lymphocytes (CYP + AIT CON), and CYP + AIT with GEM treated donor 
lymphocytes (CYP + AIT GEM). CYP (100mg/kg) was given three days after tumor 
inoculation and AIT was given 24hrs after CYP treatment at a dose of 18x106 T 
cells/mouse. Data shown is mean tumor area ± SE (6-12 mice/group).  A significant 
difference in mean tumor area was found using ANOVA (F(3,26) = 11.7, p-value < 
0.0001).  Asterisks of different colors represent significant differences (Tukey-Kramer 
HSD, p-value <0.05).    
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Rapid Tumor Kinetics Inhibit Therapeutic Effects of Combination Chemoimmunotherapy 
 
 We have attempted to use GEM to augment the immune function of donor T cells. 
Similarly, GEM might also be used to improve immune function in the recipient.  By 
inhibiting MDSC accumulation in the recipient, GEM treatment might prevent MDSC 
mediated suppression of T cell immunity and thereby, increase antitumor immunity after 
AIT.   Therefore, we performed an AIT experiment in combination with GEM treatment 
(Fig. 13).  AIT, under the conditions we have set, did not inhibit tumor growth without 
GEM.  AIT with GEM inhibited tumor growth, but this inhibition was caused by the direct 
tumoricidal effects of GEM and not by antitumor activities of transferred T cells.     
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Figure 13: AIT in Combination with early treatment of GEM is Ineffective against 7 
Day Old 4T1 Flank Tumors Given at an Initial Dose of 50,000 4T1 cells/mouse.  
Recipient Balb/c mice were inoculated with 50,000 4T1 cells in the flank and randomly 
divided into four treatment groups: untreated controls (CON), GEM treated (GEM ONLY), 
AIT treated (AIT ONLY), and GEM combined with AIT (GEM + AIT). GEM treatment 
was given on days 6 and 11 at a dose of 60mg/kg. AIT was given on day 7 using 4T1 
sensitized DLN cells at a dose of 50x106 cells per mouse.  Data shown is mean tumor area 
± SE (6 mice/group). A significant difference in mean tumor area was found using 
ANOVA (F(3,20) = 36.8, p-value<0.0001).  Asterisks of different colors represent 
significant differences (Tukey-Kramer HSD, p-value <0.05).    
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Conclusions  
 
Our results demonstrate that GEM caused delayed tumor growth and suppression of 
MDSCs, in a T cell independent manner (Fig. 6-8).  We performed follow up experiments 
to determine whether or not the elimination of MDSCs was a direct effect of the drug or an 
indirect effect that resulted from an inhibition of tumor growth.  We found that GEM acts 
on both cell populations.  GEM inhibited 4T1 mammary carcinoma cell growth in a dose 
dependent manner and directly inhibited MDSCs, in a manner independent of its effect on 
tumor growth (Fig. 7, Table 3).  The latter conclusion is based on the observation that late 
gemcitabine treatment of 20+ day tumor bearing BALB/c mice abrogated splenomegaly, 
reduced MDSC proportion in the spleen, bone marrow and blood, and restored T cell 
proliferation and effector function, despite little change in tumor size (tumor size was not 
greatly affected with just 24hr-48hr gemcitabine treatment) (Fig. 9, 10, 11).  AIT 
performed in conjunction with GEM treatment of donors or recipients was not successful 
as expected and reveal technical problems that need to be addressed in the future.    
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{CHAPTER 5: Discussion} 
 
Employing Alternate Common Gamma Chain Cytokines for T cell Expansion 
IL-2 is the primary cytokine that drives the induction of cellular immunity.  
Therefore, it is the prototypical cytokine used for the expansion of CD8+ T cells.  
Supporting this status quo, Carrio et al. showed that IL-2 always induced greater 
proliferation and IFN-γ secretion than IL-7 or IL-15 alone 57.  This difference is partly due 
to the preferential selection of effector T cells by IL-2 and selection of memory T cells by 
IL-7 and IL-1550, 57.  Mice treated with IL-7 or IL-15 in conjunction with tumor antigen 
showed exaggerated contraction of the effector pool which led to improved survival of the 
much smaller memory pool. On the other hand, mice treated with IL-2 showed inferior 
contraction of the effector pool which may account for the much greater number of T cells 
observed with IL-2 stimulation.  Despite this, our preliminary data contrast data presented 
by Carrio et al., showing that IL-7 or IL-15 expands T cells to a greater than IL-2.  The 
contradictory results may be caused by a difference in the protocol used to produce 
activated T cells.  Carrio et al. activated T cells by pulsing splenocytes with specific 
peptide while our protocol employs pharmacological activation with bryostatin-1 and 
ionomycin.  The different activation protocol used may result in a difference in T cell 
fitness.  T cell fitness is defined by resistance to cell death and responsiveness to 
homeostatic cytokines.  Withdrawal of antigen signaling causes death by neglect and 
continued T cell persistence requires survival signals through survival promoting receptors.  
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IL-7 and IL-15 are homeostatic cytokines that promote survival.  The signal strength 
received through the TCR also plays a role in prolonging T cell survival both in vitro and 
in vivo by regulating the capacity of primed T cells to respond to homeostatic cytokines, to 
survive cytokine withdrawal, and to accumulate in vivo45.   It is possible that T cell 
activation with bryostatin-1 and ionomycin produces stronger TCR signaling which 
increases the capacity of sensitized T cells to respond to homeostatic cytokines, like IL-7 
and IL-15. 
Melchionda et al. showed that IL-7 and IL-15 were comparable or better than IL-2 
at expanding Ag sensitized CD8+ T cells when given as an adjuvant in vivo along with 
immunization50.  There was no additive or synergistic effect when IL-7 and IL-15 were 
combined.  In our in vitro B/I activation model, we have shown that the combination of IL-
7 and IL-15 has an additive effect on expansion, increasing T cell numbers 8 to 9-fold over 
IL-2 (Fig.2).  We found that this difference in expansion was partly due to the protective 
roles of IL-7 and IL-15 against apoptosis47, 51, 52, 55, 56.    By day 6 of expansion, 40% of IL-
2 expanded T cells were in apoptosis (Fig. 3).  In contrast, only about 18% of IL-7/15 
expanded T cells were apoptotic.  The greater rate of apoptosis in IL-2 expanded cells may 
be the result of IL-2 mediated activation induced cell death58, 59.  To strengthen this 
argument, future experiments should look for differences in expression levels of FasL and 
anti-apoptotic molecules, like Bcl-2 and Bcl-XL, and pro-apoptotic molecules, like Bax.   
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Similar to B/I activation + IL-2 and culture in IL-2, expansion with IL-7/15 also 
selects for T cells (Table1).  After activation with B/I + IL-2 or IL-7/15, we saw an 
increase in CD44, a decrease in CD62L and an increase in CD69.  CD44 is a marker for 
the memory cells.  CD62L is a marker for effector cells and in combination with CD44 
differentiate between effector memory and central memory T cells.  CD69 is a marker for 
activated cells that is upregulated after T cell activation and is downregulated after 24 
hours.  As expected, we saw a decline in CD69 after Day 1.  Several publications have 
noted that IL-2, IL-7, and IL-15 induce different subsets of T cells48, 50, 54.  Both IL-7 and 
IL-15 are important in regulating background survival and turnover of central memory T 
cells (CD44highCD62LhighCD69
-
) while IL-2 maintains the effector phenotype 
(CD44highCD62LlowCD69+).  Mechionda et al.  found that, in vivo, IL-7 and IL-15 initially 
expanded effector T cell pools similar to IL-2, but this expansion resulted in long-term 
development of antigen specific memory T cells50.  Similar to their results, we found that 
IL-7/IL-15 initially induced similar T cell subsets as IL-2 (Table 1).  These cytokines 
selected for effector memory CD8+ T cells (CD44highCD62Llow), which displayed similar 
phenotypic and functional properties as effector cells but persist longer after Ag 
clearance57.  However, by day 3 we began to see a divergence and by day 6 there was a 
substantial difference in T cell subsets.  IL-7/15 expanded cells maintained a central 
memory CD8+ T cells (CD44highCD62Lhigh), which are functionally and phenotypically 
different from effector memory cells (TEM).  This induction of the central memory 
phenotype (TCM) is desirable because less differentiated, central memory like T cells have 
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been dubbed the optimal population for AIT because of their greater fitness compared to 
effector cells63.  On the other hand, IL-2 favored expansion of CD4+ T cells and T cells 
with an effector phenotype with a downregulation of the memory phenotype, which may 
help explain the cells’ lack of persistence.  Because IL-2 plays a pivotal role in the 
development of Treg cells (CD4+CD25+FOXP3+), it may be possible that the shift to 
CD4+ cells is indicative of an increase in Treg cells46, 61, 62. This would contribute to the 
impaired expansion of IL-2 stimulated cells compared to IL-7/15 stimulated cells.  To 
confirm this, future experiments should look for FOXP3+ cells in addition to the other T 
cell subsets.  
In addition, despite the increase in TCM cells, we also found that IL-7/15 expanded 
cells increased their IFN-γ response to specific antigen stimulation over time while IL-2 
cultured cells showed a decline in IFN-γ response (Fig. 4).  Because IFN-γ is a product of 
activated CD8+ T cells, the change in the production of this cytokine in response to 
specific peptide may reflect the decline in the proportion of CD8+ T cells over time in IL-2 
cultures (Table 1).  Similarly, the maintenance of high antitumor responses by IL-7/15 
expanded T cells on Day 3 and 7 reflect the persistence of a large, viable CD8+ T cell 
population in IL-7/15 cultures.  In addition, it may reflect a transition from an effector 
memory to a central memory phenotype.  Central memory cells have enhanced sensitivity 
to Ag that leads to a rapid activation of effector functions, which may explain our observed 
increase in response to Ag over time 57.     
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One of the concerns of in vitro expansion is that it shortens the lifespan of antigen-
sensitized T cells in vivo after adoptive transfer.  Repeated in vitro stimulation of human T 
cells resulted in progressive decrease in telomerase activity and shortening of telomeres 93.  
This eventually led to replicative senescence and an impaired ability of the adoptively 
transferred T cells to mediate antitumor responses.  In addition, in vitro conditions for 
generating large numbers of antigen specific T cells may alter the function of CD8+ T cells 
in vivo. In fact, a review by Gattinoni et al. suggested an inverse relationship of in vitro 
and in vivo antitumor function of adoptively transferred T cells 63.  The ability of IL-7/15 
cells to persist in culture for a longer period of time might be indicative of their ability to 
persist in vivo (Fig. 2).  Our results showed that IL-7/15 expanded cells were able to persist 
in vivo and mediated regression of pulmonary metastases in 100% of treated mice 
compared to 17% with the same number of IL-2 expanded cells.  Although our treatment 
was therapeutic, it is difficult to tell whether or not it correlates with the differences 
observed in IL-2 and IL-7/15 cultures in vitro.  Therefore, in vivo assays should be 
conducted to show that IL- 7/15 cells expand and persist better in vivo and maintain their 
potent central memory phenotype and functions.  
We have shown that with alternate gamma chain cytokines, like the combination of 
IL-7 and IL-15, greater numbers of T cells with the same or greater antitumor efficacy as 
IL-2 expanded cells can be produced.  This is invaluable for the success of AIT, which is 
dependent on both the quantity and quality of effector cells.  The ratio of antigen specific T 
cells to tumor cells determines the kinetic balance between the rate of tumor growth and 
the strength and duration of the immune response.  The ability to get large numbers of T 
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cells that can persist and respond to tumor in vivo in less time will help drive the 
development of more efficient and less costly treatment plans for cancer patients.   
 
Abrogating Immunosuppression of Myeloid Derived Suppressor Cells with 
Gemcitabine 
Even if large numbers of functional T cells are administered, adoptive T cell 
therapy may still be unsuccessful in controlling infection or malignancy, due to multiple 
mechanisms of tumor evasion.  Conversely, tumor-induced immunosuppression may 
inhibit the production of T cells with therapeutic activity from the tumor bearing host.  One 
such mechanism of immunosuppression is caused by myeloid derived suppressor cells 
(MDSCs), which accumulate in association with increasing tumor burden, leading to 
splenomegaly (Fig. 6).  MDSCs reduce antigen specific CD8+ T cell proliferation, increase 
death by apoptosis, foster T cell tolerance, and change the profile of cytokines secreted by 
activated T lymphocytes70, 72, 74, 76.  They exert their immunosuppressive effects primarily 
through the secretion of arginase I (ARG-1) and nitric oxide synthase, leading to L-
arginine starvation, production of urea, generation of NO, and the creation of reactive 
nitrogen oxide and reactive oxide species (NOS-2) 70, 72, 75, 77-80.  In addition to direct 
inhibition of T cells through ARG-1 and NOS-2, MDSCs also indirectly inhibit 
development of cytotoxic T cells by driving the formation of alternate macrophages that 
favor a Th2 response and thereby, promote tumor progression81.  MDSCs also inhibit T 
cell function by inducing the development of CD4+CD25+FoxP3+ T regulatory cells in 
vitro and in vivo95.  This inhibition was dependent on IFN-γ stimulated secretion of IL-10 
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and transforming growth factor (TGF-β) from MDSCs.  Thus, the induction of MDSCs 
represents a mechanism of tumor induced immune suppression that may be responsible for 
the inability of T cells from tumor bearing hosts to recognize tumor antigen, expand in 
vitro and/or eliminate tumor cells. 
Depletion of MDSCs may help to create a better host environment that is more 
conducive to the activation of antitumor immunity after AIT and may rescue antitumor 
immunity in tumor bearing hosts.  Gemcitabine has recently been reported to be an 
effective treatment against MDSCs without severely harming activated immune cells81, 85, 
96-97.  An investigation of the effect of GEM on immune cells in patients with pancreatic 
adenocarcinoma revealed that GEM decreased memory T cell function, but enhanced naive 
cell activation97.  Treatment with GEM did not interfere with Th1-cell activation and 
production of Th1 cytokines but may inhibit Th2 immunity.   Thus, while GEM does have 
some negative side effects, it seems to produce more positive than negative responses.   
Before application against MDSCs, GEM was used against metastatic cancers as an 
FDA approved antimetabolite with tumoricidal effects86.    This cytidine analogue acts 
during the S phase of the cell cycle.  Thus, rapidly dividing cells, like cancer cells, are 
highly susceptible to the drug’s impairment of DNA synthesis.  If the tumor 
microenvironment induces myelopoeisis, it is possible that GEM would also act on 
MDSCs to inhibit their accumulation by inhibiting the formation of immature myeloid 
cells.  In addition, GEM distributes to areas in which MDSCs have been known to collect, 
like the spleen, femur, and lymph nodes, which gives the drug the opportunity to operate 
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on this cell population.  We have observed that in mice with established 4T1 flank tumors, 
GEM, administered soon after tumor inoculation and repeated once a week at a dose of 
60mg/kg, delayed tumor progression, prevented splenomegaly, and suppressed MDSC 
accumulation in the spleens (Fig. 6).  Our results verified the work by Sinha et al. who had 
similar data from the same 4T1 tumor model and work by Ko et al, who used a tolerogenic 
Her-2/neu induced tumor model85, 96.  Both groups claimed that the inhibition of tumor 
progression was a result of direct inhibition of MDSCs by GEM.  However, their 
experiments lacked rigorous evidence to support a direct effect of GEM on MDSCs.  
Because GEM has an influence on both tumor growth and MDSC numbers, it is difficult to 
determine which effect comes first.  The purpose of our studies was to elucidate the 
mechanisms by which GEM exerted its pharmacologic effects on MDSCs.  Our goal was 
to determine whether the observed suppression of MDSCs is a direct effect of the drug or 
an indirect result of cytotoxicity to tumor cells.  Doing so may help determine whether 
GEM is a good treatment option for abrogating the immunosuppression caused by MDSCs, 
especially for tumors that are not susceptible to GEM’s direct cytotoxic effect.   
Figure 14 represents the ways in which GEM may act.  In tumor bearing mice, the 
tumor cells secrete factors that lead to the development of MDSCs, which in turn, inhibit T 
cell function by the secretion of arginase-1 and nitric oxide synthase and indirectly by the 
induction of Treg cells and M2 macrophages (Fig. 14A).  If GEM directly inhibits MDSC 
accumulation, we would see an abrogation of immunosuppression, which would allow the 
immune response to recover and impair tumor progression.  Thus, any decrease in tumor 
120 
 
size after GEM administration would be a result of an immune response rescued by GEM 
treatment, acting directly on MDSCs. (Fig. 14B).  On the other hand, if the drug directly 
inhibits tumor growth, it would prevent MDSC accumulation (Fig. 14C).  Therefore, we 
would see a decrease in both tumor size and MDSC accumulation in treated animals.  
However, the inhibition of tumor progression would be predominantly a direct cytotoxic 
effect of GEM on tumor cells, not an immune mediated one.  The last possible scenario is 
one in which GEM acts on both cell populations (Fig. 14D).  
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Figure 14: Potential Mechanisms of GEM Pharmacologic Effects.  
(A) In untreated mice, tumor cells secrete factors that induce MDSC development and 
cause T cell dysfunction.  (B) GEM acts directly on MDSCs and by releasing T cells from 
inhibition by MDSCs, mediates immune dependent inhibition of tumor progression (C) 
GEM inhibits tumor cells directly, inhibiting tumor growth and indirectly preventing the 
accumulation of MDSCs and impair tumor growth pharmacologically. (D) GEM inhibits 
both MDSCs and tumor cells directly. 
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Through in vitro assays, we have shown that GEM does indeed directly inhibit 4T1 
tumor cell growth (Fig. 7, Table 3), corroborating the dose dependent cytotoxicity 
observed by Smith et al. on endometrial cancer cells94.  We also hypothesized that despite 
this direct effect on tumor cells, GEM might still directly inhibit MDSCs.  Since MDSCs 
suppress T cell immunity, we reasoned that part of the impaired tumor growth seen in 
GEM treated mice might be caused by abrogation of T cell inhibition.  Therefore, if GEM 
were given to athymic nude mice that lacked T cells, the inhibition of tumor growth in 
GEM treated mice would be dampened.  This would provide evidence that at least part of 
GEM’s effect on tumor growth in vivo results from direct inhibition of MDSCs.  However, 
contrary to this hypothesis, GEM treatment caused a similar delay in tumor growth in nude 
mice as in BALB/c mice (Fig. 8).  Thus, it would seem that even if GEM does act directly 
on MDSCs, the inhibition of tumor progression in vivo is independent of T cells.  The 
results here substantiated previous findings that elimination of CD8+ T cells had no effect 
on the antitumor effect of this chemotherapy drug96.  Although GEM mediated effects on 
tumor growth in vivo were independent of T cells, the amplified immune response 
generated by AIT in combination with GEM was dependent on C8+ T cell activity96, 98. 
Even though GEM has a potent direct anti-tumor effect in the 4T1 model, it may 
also inhibit MDSC directly and have potential for augmenting immunotherapy (Fig. 14D).  
Although the results of our experiment in nude mice did not demonstrate whether or not 
GEM acts directly on MDSCs, our next experiment did help answer the question.  When 
we treated mice bearing large established tumors (>60mm2) with GEM, we saw little 
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change in the tumor size compared to untreated mice (Figs. 9 and 10).  Nevertheless, 
splenomegaly was reversed within 24hr after treatment and MDSC numbers were 
decreased in the blood, bone marrow, and spleen.  All three tissues are known sites where 
MDSCs accumulate and where GEM is distributed after administration92.  These results 
support the hypothesis that GEM inhibits MDSCs directly and verify in the 4T1 tumor 
model experiments presented by Suzuki et al in the TC-1 lung epithelial tumor model and 
by Ko et al. in the Her-2/neu breast cancer model85, 96.  Although their results, which were 
obtained 48hrs after GEM treatment, were convincing, our analysis after only 24hrs and 
with half the dose of GEM further substantiates the direct effect of GEM on MDSCs.  In 
just 24hr or 48hr after GEM treatment, when our analysis was performed, there was not 
enough time for tumor size to change, so the GEM effects on MDSCs are unlikely to be 
attributable to the drug’s cytotoxicity against the tumor.  Therefore, it seems likely that 
GEM works on both tumor cells and MDSCs.  To verify further that GEM acts directly on 
MDSCs, future experiments could assay for differences in MDSC products, like ARG-1 
and NOS-2 in the spleen and bone marrow of treated and untreated mice.  Apoptotic cells 
at the tumor site and at MDSC locations should be measured to confirm inhibition of these 
cells by GEM.  
The inhibitory effects of GEM on MDSCs suggest that GEM treated tumor bearing mice 
should have less immunosuppression than untreated mice with upregulated suppressor 
cells.  Indeed, we showed a novel association between GEM treatment , decreased 
MDSCs, and improved T cell proliferation. Splenic lymphocytes from treated mice were 
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better able to respond to activation signals and to proliferate in response to cytokines than 
lymphocytes from untreated controls (Fig. 11).  This improvement was correlated to 
reduction in MDSCs in tumor bearing mice after GEM treatment.  In addition, 
lymphocytes from untreated 4T1 bearing mice were unresponsive to tumor, but were 
rescued by removal from the immunosuppressive host environment and B/I activation, so 
that after expansion (albeit markedly reduced compared to GEM-treated mice), splenic 
lymphocytes secreted IGN-γ in response to specific tumor antigen at levels similar to cells 
from treated mice (Fig. 11).     
The ability of GEM to rescue tolerant T cells from hosts with established tumors 
may prove useful for augmenting AIT in the clinic.  At the time of diagnosis, many 
patients have advanced tumor progression, with T cells that are already immunosuppressed 
and dysfunctional.  Treatment with GEM mitigated this suppression and functional T cells 
were harvested.  To help combat the kinetics of disease progression, it is important to be 
able to harvest functional Ag-specific T cells and quickly expand these cells to therapeutic 
numbers for adoptive transfer as soon as possible.  Thus, GEM has the potential to 
augment AIT in two ways.  Donors can be treated to increase the responsiveness of tumor 
primed T cells at the time of harvest to in vitro manipulation.  In addition, treatment of 
tumor-bearing recipients (identical to the donor in most human AIT paradigms) before 
infusion of T cells might create a more conducive environment for T cell proliferation and 
persistence.   
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Other researchers have demonstrated the benefits of inhibiting MDSCs in cancer 
therapy71, 79, 83, 84.  Using anti-Gr-1 antibody, Seung et al showed that depletion of MDSCs 
alone was able to cause complete rejection of a progressive tumor induced by UV light83.  
Sinha et al. suggested that induction of M1 macrophages and reduction of MDSCs by 
surgical removal of established 4T1 mammary carcinoma and treatment with all-trans-
retinoic acid (ATRA) could result in rejection of established tumors71.  Treatment of mice 
bearing C3 fibrosarcoma or DA3-HA mammary adenocarcinoma with ATRA decreased 
MDSC number in the spleen, lymph nodes, and bone marrow by inducing differentiation 
into mature dendritic cells84.  Kusmartsev et al. demonstrated that ATRA given in 
combination with vaccination to mice with C3 fibrosarcoma broke T cell tolerance and 
increased expansion of Ag-specific, IL-2 producing CD4+ T cells as well as expansion of 
Ag-specific IFN-γ producing CD8+ T cells, and led to impaired tumor growth.  Similar to 
our data, their study found that only T cells from MDSC depleted tumor bearing mice 
showed Ag-specific IFN-γ responses.  All of these findings suggest that mitigating the 
immunosuppressive effects of MDSCs can augment cancer therapy.  Therefore, GEM 
might also display similar successes when combined with AIT by inhibiting MDSCs.    
As of today, GEM has not been used in the clinic for the purpose of inhibiting 
immunosuppression by MDSCs.  Its success in the clinic has been attributed to its direct 
tumoricidal effects86, 94.  Therefore, it has been used as a single agent or in combination 
with other chemotherapy drugs and in conjunction with AIT.  When GEM has been 
combined with AIT, positive responses were attributed to the drug’s direct antitumor 
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effects98, 101.  For example, Nowak et al. used GEM in conjunction with AIT and activating 
anti-CD40 ligand, which led to complete regression of AB1 murine malignant 
mesothelioma and induced protective immune memory98.  This response could not be 
achieved without GEM treatment.  The researchers asserted that GEM augmented 
combination therapy by inducing apoptosis of tumor cells and by increasing CD4+ and 
CD8+ T cell infiltration of the tumor98, 99.  The authors attributed the latter to GEM’s direct 
anti-tumor effect and abrogation of humoral immunity.  Specifically, the researchers found 
that GEM treatment of tumor bearing mice increased CD8+ T cell proliferation and 
cytolytic function.  They reasoned that this was caused by an increase in tumor antigen 
cross-presentation induced by GEM mediated tumor cell apoptosis99.  In addition, they 
found that GEM treatment of mice with established AB1 murine mesothelioma resulted in 
depleted serum antibody titer100.  However, their results could also have been explained by 
GEM mediated suppression of MDSCs.  The tumor site is one location where MDSC 
accumulation is observed in mice with large tumor burdens.  If GEM causes the MDSC 
proportion to decrease at the tumor site, an increase in the proportion of other cell 
populations, like CD4+ and CD8+ T cells, would result.  Because MDSCs inhibit T cells 
and drive the development of a Th2 immune response, suppression of MDSCs by GEM 
would also lead to increased T cell responsiveness and decreased humoral responses, as 
observed by Nowak et al70, 72, 74, 76, 81.  As demonstrated, positive results can be obtained by 
using GEM as a traditional tumoricidal antimetabolite in conjunction with AIT.  However, 
better results and more optimal conditions for AIT might be obtained by focusing on the 
pharmacologic targets of GEM (i.e. by targeting both tumor cells and MDSCs). 
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Ko et al. have begun utilizing GEM in combined chemoimmunotherapy in a 
tolerogenic Her-2/neu murine tumor model.  Similar to our strategy, they targeted Treg 
cells and attempted to abrogate immunosuppression by MDSCs.  When we examined the 
combined effects of cyclophosphamide, which can inhibit Treg cells, and GEM we saw 
antitumor effects that mirrored the groups treated with GEM alone, with no additive 
effects.  Using anti-GITR antibody to deplete Treg cells in combination with GEM, Ko et 
al. made the same observations96.  Targeting both Treg cells and MDSCs may not have 
eradicated established tumors on their own, but in combination with AIT, this 
chemoimmunotherapy led to better outcomes than either AIT with Treg cell depletion or 
AIT with MDSCs depletion.  In fact, AIT combined with inhibition of Treg cells and 
MDSCs led to a cure rate of 100% and protected cured mice against tumor rechallenge 90 
days after the first tumor inoculation.  
 Following the success of this group and other groups that have used GEM in AIT, 
our next set of experiments aimed to investigate the effects of GEM in our model of AIT.  
However, our initial combination of AIT with GEM treatment of recipients did not yield 
significant improvement in outcomes of 4T1 tumor bearing BALB/c mice (Fig. 14).  We 
attempted to treat 7 day old 4T1 tumors given at an initial concentration of 50,000 4T1 
cells/mouse with 50x106 T cells/dose.  The recipient mice were treated with GEM 24hrs 
before AIT and again a week later.  Failure of this combination therapy to inhibit tumor 
progression might be attributed to several factors.  The first is the failure of GEM 
treatment at day 7 and day 11 to inhibit MDSCs that only accumulate in our model when 
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mice have developed large tumor burdens (Fig. 6).  It is therefore difficult to use this 
model to show that GEM inhibition of MDSCs augment AIT.  It is not practical to use 
GEM to treat MDSCs at their time of accumulation, when tumor area has reached 
≥60mm2, because the tumor burden would too great to be treated by AIT before mice have 
to be euthanized.  Giving GEM early and repeatedly would make it difficult to distinguish 
direct tumoricidal effects from MDSC inhibition.  Therefore, to investigate benefits of 
GEM induced inhibition of MDSCs in AIT, a different tumor model should be employed, 
one that induces the accumulation of MDSCs at the early stages of tumor development.  It 
is also likely that mice given an inoculum of 50,000 4T1 cells/mouse have tumors that are 
already too advanced at day 7 to be treated by 50x106 T cells. The T cells may have 
antitumor function and proliferative capacity, but are unable to match the rapid growth of 
the tumor cells.  Future experiments can be optimized by carrying out a cell dose assay to 
determine what dose of T cells yield positive outcomes for a specific tumor inoculum and 
for a specific treatment timeline.  Furthermore, it should be noted that other 
immunosuppressive mechanisms exist besides MDSCs that thwart T cell immunity, like 
Treg cells and cytokine sinks.  Our lab typically combines AIT with CYP to create a host 
environment more conducive to AIT.  CYP may be important in helping maintain T cell 
fitness in vivo and should be used in future AIT experiments.     
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While other groups have used GEM to treat recipient mice, we additionally 
questioned whether or not GEM augments AIT when used to treat donors.  Because T cells 
from GEM treated mice with large tumors showed a significant qualitative and quantitative 
difference compared to T cells from untreated, tumor bearing mice, we wondered whether 
or not GEM rescued T cell function would extend in vivo and eradicate 4T1 flank tumors.  
4T1 flank tumors are difficult to cure with T cells from Ag vaccinated mice.  Thus, if T 
cells from mice with such advanced tumors can mediate an immune response against 
established tumor, a strong argument can be made for the use of GEM to treat donors 
before T cell harvest.  
To test this hypothesis we performed a preliminary AIT experiment using T cells 
harvested from mice bearing 22 day old tumors (Fig. 12).  The mice were either untreated 
or treated with GEM 48hrs before T cell harvest.  The failure of AIT using lymphocytes 
from donors with advanced tumors to inhibit tumor progression demonstrate difficulties 
faced in the clinic.  T cells from hosts with well established tumors are dysfunctional or 
absent due to immunosuppression from a variety of tumor induced mechanisms making it 
difficult to harvest sufficient numbers of tumor-specific, functional T cells.  We used 
18x106 T cells/mouse, which was not therapeutic.  It is likely that even if the T cells were 
able to respond to tumor antigens, as shown in figure 11, this dose was too small to 
compete with the rapid growth of tumor cells at the given dose of 10,000 4T1 cells/mouse.  
Following AIT experiments should employ a larger dose of T cells.  In addition, because 
the T cells were harvested from mice with advanced tumors, they were likely to be less fit 
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and therefore, less able to persist and carry out effector functions in vivo.  Future studies 
would have to follow T cell lifespan and proliferation in vivo to confirm this.  Tumor 
escape mechanisms, such as mutation of specific antigen or downregulation of key MHC 
molecules, could also account for the lack of T cell effectiveness.       
AIT has had such limited success in the clinic against most cancers because it is 
dependent on so many factors and overcoming multiple obstacles.  Successful AIT 
depends on the type of cells used for adoptive transfer, the reversal of tolerance and 
immune dysfunction, the generation and expansion Ag-specific cells, and the in vivo 
persistence and avidity of transferred cells.  In addition, immune suppression in the 
adoptive host must be abrogated to ensure that fit Ag-specific cells can traffick to the 
tumor site and target tumor cells.   We have found that by exploring new ways to augment 
T cell expansion, we may make adoptive immunotherapy more effective as a treatment 
against cancer.  Not only would we increase the likelihood that AIT is successful against 
tumor development, we would be able to make the treatment less costly in terms of labor, 
time and expenses.  This will prove prudent in a world where cancer is quickly becoming a 
problem for both resource rich and resource poor countries. 
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